Methods and Uses of Microbiota Compositions, Components, or Metabolites for Treating Vagus Nerve-Related Diseases, Disorders, and Conditions
Microbiota compositions targeting the vagus nerve and its organs improve signal transmission and reduce inflammation, addressing the systemic dysfunction of the vagal axis.
Patent Information
- Application Number
- JP2024532707
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-04-12
- Filing Date
- 2022-12-01
- Publication Date
- 2024-11-15
AI Technical Summary
Current treatments for vagus nerve-related diseases and disorders are inadequate, as they primarily target specific organs rather than addressing the overall dysfunction along the vagal axis, including the brain, vagus nerve, and connecting organs.
Microbiota compositions comprising specific microbial strains and their metabolites are administered to improve the function of the vagus nerve and its connecting organs, enhancing basal cellular functions and modulating inflammation and immunity, thereby improving signal transmission and reducing neuroinflammation.
The compositions enhance the overall function of the vagus nerve system, leading to reduced inflammation, improved organ connections, and better signal delivery, resulting in comprehensive performance improvements.
Smart Images

Figure 2024542727000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 285,383, filed December 2, 2021, and U.S. Provisional Patent Application No. 63 / 330,149, filed April 12, 2022, each of which is incorporated by reference in its entirety herein. [Background technology]
[0002] Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), autism spectrum disorder (ASD), rheumatoid arthritis, hypertension, heart failure, diabetes, arrhythmia, inflammatory bowel disease (IBD), fatty liver disease, depression, epilepsy, bipolar disorder, anxiety, post-traumatic stress disorder (PTSD), multiple sclerosis (MS), autoimmune diseases, obesity, acute pancreatitis (AP), eye diseases including retinal ischemia / reperfusion (I / R) injury, chronic obstructive pulmonary disease (COPD), and chronic myocardial infarction (CHD). Many diseases, disorders, or conditions are suspected to be related to vagus nerve dysfunction, including, but not limited to, psoriasis and psoriatic arthropathy, endocrine tumors and vagal paragangliomas, heartburn, gastroesophageal reflux disease (GERD), small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), celiac disease, chronic constipation, kidney disease, endometriosis, aging, and infertility, including vascular disease. Currently, there are no effective treatments to improve and / or treat overall health, well-being, and function of the vagus nerve, and thus vagus nerve-related diseases, disorders, and conditions (including, for example, diseases of any organ connected to the vagus nerve), and finding new drugs or treatment methods is a priority. Summary of the Invention
[0003] The disclosure relates to compositions (e.g., microbiota compositions) and methods described herein that are useful for treating a disease, disorder, or condition in a subject (e.g., a mammal (e.g., human, mouse, etc.)) (e.g., those associated with the vagus nerve (e.g., any disease of an organ that connects to the vagus nerve, e.g., a neurodegenerative disease, disorder, or condition (e.g., AD, PD, ALS, autism spectrum disorder, epilepsy, bipolar disorder, etc.), rheumatoid arthritis, hypertension, heart failure, diabetes, arrhythmia, IBD, fatty liver disease, depression, anxiety, PTSD, MS, autoimmune disease, obesity, AP, retinal ischemia / conditions, etc., including, but not limited to, retinal ischemia / conditions ... ocular disorders including I / R injury, COPD, mood disorders, migraines and cluster headaches, eating disorders, anorexia, psoriasis and psoriatic arthritis, endocrine tumors and vagus nerve paragangliomas, heartburn, GERD, SIBO, IBS, celiac disease, chronic constipation, kidney disease, endometriosis, aging, infertility including vascular disease, etc. Additionally, the disclosure provides insight that the compositions (e.g., microbiota compositions) and methods described herein can be used to treat and / or improve the health of one or more components of the vagus nerve itself (e.g., hepatic vasculitis) in a subject. It is further understood that the compositions (e.g., microbiota compositions) and methods described herein can be used to treat and / or improve the health and overall function of any organ, tissue, and / or other internal part of a subject. Among other things, the disclosure describes techniques that can be used to treat, prevent, and / or reduce the risk of (e.g., vagus nerve-related) diseases, disorders, or conditions. In some embodiments, the disclosure describes compositions and methods for assessing the effect of administering such compositions (e.g., microbiota compositions described herein) to a subject and / or for identifying or characterizing the effect and / or modulation of the levels of metabolites or metabolome in a subject upon administration of such compositions.In some embodiments, the metabolites that can be modulated can be associated with a particular disease, disorder, or condition. In some embodiments, such techniques can be useful for identifying metabolite level differences in a particular subject (e.g., patient) or population (e.g., before and after administration of a disclosed composition). Thus, the present disclosure also provides techniques that can be useful for identifying and / or evaluating the properties and effects of the disclosed compositions in specific subjects (e.g., patients) and / or populations, and thus providing subject-specific information on how to treat a disease, disorder, or condition (e.g., of the nervous system) in an individual subject or individual population. For example, in some embodiments, the techniques provided herein can be useful for treating and / or preventing a disease, disorder, or condition (e.g., associated with the vagus nerve) by identifying a subject-specific composition based on the metabolome in a subject-specific sample and administering a disclosed composition (e.g., a subject-specific composition) (e.g., to modulate the metabolome of the subject). Thus, the technology described herein may be useful as therapeutic agents and tools for reducing the risk of certain diseases, disorders, or conditions (e.g., related to the vagus nerve) and for treating and / or preventing such diseases, disorders, or conditions.
[0004] The present disclosure realizes the insight that the compositions described herein (e.g., microbiota compositions) directly affect the end-to-end function of the system involving the vagus nerve. Prior art has been limited to treating only a portion of such a system, e.g., dysfunction associated with a specific organ. The present disclosure recognizes that such techniques, while beneficial, only triage a portion of the overall problem. Thus, the present disclosure provides compositions and methods targeted to improving function along the entire vagal axis, including, for example, the function of the brain, the vagus nerve, and one or more connected organs.
[0005] In some embodiments, the compositions described herein improve cellular mitochondrial, lysosomal, proteasomal, and / or peroxisomal function of all four major components of the vagus nerve (see Vagus Disorders Associated Diseases, Disorders, and Conditions (i.e., (i) one or more organs, (ii) nerve endings, (iii) nerve fibers, and (iv) brain)). Additionally, in some embodiments, the compositions described herein improve other pathways associated with or in these components that reduce inflammation and properly regulate immunity. In some embodiments, these effects result in comprehensive performance improvements throughout the system, including, but not limited to, healthier organ connectivity, better sensing and improved delivery in nerve endings, improved signal quality as signals travel in either direction through the vagus nerve, and reduced overall inflammation, including in the vagus nerve and neuroinflammation, along with restored and / or improved brain function.
[0006] Among other things, the disclosure provides methods of treating, reducing the risk of, ameliorating, or preventing a vagus nerve-related disease, disorder, or condition. In some embodiments, the method comprises administering a composition comprising one or more microbial strains, components thereof, or metabolites thereof to a subject in need thereof. In some embodiments, the method comprises administering a composition comprising one or more metabolites to a subject. In some embodiments, the vagus nerve-related disease, disorder, or condition is selected from the group consisting of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), autism spectrum disorder, rheumatoid arthritis, hypertension, heart failure, diabetes, arrhythmia, inflammatory bowel disease (IBD), fatty liver disease, depression, epilepsy, bipolar disorder, anxiety, post-traumatic stress disorder (PTSD), multiple sclerosis (MS), autoimmune disease, obesity, acute pancreatic cancer, and the like. These include eye diseases including acute myelitis (AP), retinal ischemia / reperfusion (I / R) injury, chronic obstructive pulmonary disease (COPD), mood disorders, migraine and cluster headaches, eating disorders, anorexia, psoriasis and psoriatic arthropathy, endocrine tumors and vagus paragangliomas, heartburn, gastroesophageal reflux disease (GERD), small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), celiac disease, chronic constipation, kidney disease, endometriosis, aging, or infertility including vascular disease.
[0007] In some embodiments, the methods include treating, reducing the risk of, ameliorating, or preventing one or more of nerve cell injury, nerve ending injury, nerve fiber injury, brain injury, vagus nerve-associated organ injury, or a combination thereof.
[0008] In some embodiments, the subject is an animal. In some embodiments, the subject is a mammal, for example, a mammal experiencing or susceptible to a disease, disorder, or condition described herein. In some embodiments, the animal is a vertebrate, for example, a mammal such as a non-human primate (especially a higher primate), sheep, dog, rodent (e.g., mouse or rat), guinea pig, goat, pig, cat, rabbit, or cow. In some embodiments, the animal is a non-mammal, such as a chicken, amphibian, reptile, or invertebrate. In some embodiments, the subject is a human.
[0009] In some embodiments, the subject suffers from or is susceptible to one or more vagus nerve-related diseases, disorders, or conditions described herein. In some embodiments, the subject exhibits one or more symptoms of one or more vagus nerve-related diseases, disorders, or conditions. In some embodiments, the subject has been diagnosed with one or more vagus nerve-related diseases, disorders, or conditions described herein. In some embodiments, the subject is undergoing or has undergone a certain therapy to diagnose and / or treat one or more vagus nerve-related diseases, disorders, or conditions.
[0010] In some embodiments, one or more microbial strains are derived from an animal microbiota. In some embodiments, one or more microbial strains are derived from a mammalian microbiota. In some embodiments, one or more microbial strains are derived from a human microbiota. In some embodiments, the human microbiota is a subject's microbiota. In some embodiments, the human microbiota is administered to maintain or regulate the subject's microbiota.
[0011] In some embodiments, the one or more components or metabolites (e.g., of one or more microbial strains) are selected from Appendix 1, Appendix 3, or Appendix 4. In some embodiments, the metabolites may be derived from one or more microbial strains. In some embodiments, the metabolites may be derived from a source that is not a microbial strain, e.g., synthetically produced. In some embodiments, the one or more metabolites (e.g., of one or more microbial strains) are or include bile acids. In some embodiments, the one or more metabolites (e.g., of one or more microbial strains) are or include tauroursodeoxycholic acid. In some embodiments, the one or more components or metabolites are butyrylcamitine, theobromine, p-hydroxyphenylpyruvic acid, propionic acid, picolinic acid, 2-hydroxy-4 methylvaleric acid, N6-acetylcysine, urocanic acid, N5-ethylglutamine, trigonelline, stachydrine, ectoine, 5-hydroxylysine, arginine (Arg), cholic acid, 2-(4-hydroxyphenyl)propionic acid, N-acetyltryptophan, hydroxyproline, argininosuccinic acid, glutamic acid (Glu), sarcosine, 5-methoxyindoleacetic acid, indole-3-lactic acid, isovalerylalanine, N-acetylleucine, 1-methylhistidine, N-acetylphenylalanine, proline (Pro), or any combination thereof.In some embodiments, the one or more components or metabolites are 4-hydroxyphenylpyruvate, ectoine, gramine, N-acetyl-L-phenylalanine, nepsilon-acetyl-L-lysine, stachydrine, trigonelline, 3-ureidopropionic acid, theobromine, hippuric acid, imidazolepropionic acid, NG-methyl-L-arginine, transurocanic acid, N-acetyl-L-leucine, sarcosine, isobutyrylcalcine, acetyl-L-phenylalan ... Nitine, b-Hydroxyisovaleric acid, L-Theanine / N5-Ethylglutamine, 5-Hydroxylysine, Phenaceturic acid, Betaine, Hydroxyproline, Picolinic acid, 2-Aminoadipic acid, Glycerophosphocholine, Carnitine, Glycerol 3-phosphate, Argininosuccinic acid, Creatine, Terephthalic acid, Homocitrulline, Mucic acid, Homocysteine sulfinic acid, Trimethyllysine, Spermidine, Glyoxylic acid, XA0013 C6H6O4S, 3-indoxyl sulfate, nicotinamide, N-formylglycine, ureidoglycolate, N-methylproline, glucaric acid, butyrylcarnitine, methionine sulfoxide, carboxymethyllysine, glycolic acid, phenaceturic acid, diethanolamine, phosphorylcholine, guanidinosuccinic acid, N-acetylhistidine, glyceric acid, S-methylmethionine, cysteine glutathione disulfide, kynurenine, N-acetylphenylalanine, threonic acid, malic acid, 7,8-dihydrobiopterin, homovanillic acid, taurocholic acid, 5-methoxyindoleacetic acid, butyrate, b-hydroxyisovaleric acid, 2-oxoglutaric acid, N-acetyltryptophan, thiaproline, hypotaurine, cholic acid, acetoacetic acid, ethanolamine, guanidoacetic acid, S-sulfocysteine, myristic acid C14:0 XA0027, or any combination thereof.
[0012] In some embodiments, the one or more microbial strains are or include Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or combinations thereof. In some embodiments, the one or more microbial strains are or include Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella sp., Bifidobacterium sp., or combinations thereof. In some embodiments, the one or more microbial strains are or include Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus catus, Lactobacillus plantarum, Veillonella atypica, Bifidobacterium breve, or a combination thereof. In some embodiments, the one or more microbial strains are or include Bacillus subtilis.
[0013] In some embodiments, the composition comprises two or more microbial strains. In some embodiments, the composition comprises five or more microbial strains. In some embodiments, the composition comprises ten or more microbial strains.
[0014] In some embodiments, the composition is administered topically, orally, subcutaneously, intravenously, intramuscularly, intracerebrally, intrathecally, intrarectally, ophthalmically, intravitreally, or suprachoroidally. In some embodiments, the composition is administered orally. In some embodiments, the composition is administered intracerebrally.
[0015] In some embodiments, the composition is formulated as a syrup, liquid, tablet, lozenge, gummy, capsule, powder, gel, film, injectable, or eye drops.
[0016] In some embodiments, each microbial strain of the one or more microbial strains is 1 ~10 15 In some embodiments, each of the one or more microbial strains is present in the composition at a concentration of at least 10 CFU. 6 In some embodiments, each of the one or more microbial strains in the composition is present in the composition at a concentration of 10 CFU. 1 Colony forming units (CFU) ~10 20 In some embodiments, each of the one or more microbial strains in the composition comprises 10 1 Colony forming units (CFU) ~10 15 In some embodiments, each of the one or more microbial strains in the composition comprises 10 6 CFU~10 15 In some embodiments, each of the one or more microbial strains in the composition comprises about 10 1 CFU~10 15 CFU, or about 10 2 CFU~10 14 CFU, or about 10 3 CFU~10 13 CFU, or about 10 4 CFU~10 13 CFU, or about 10 5 CFU~10 12 CFU, or about 10 6 CFU~10 11 CFU, or about 10 7 CFU~10 10 CFU, or about 10 8 CFU~10 9 CFU, or about 10 5 CFU~10 10 CFU, or about 10 8 CFU~10 12In some embodiments, each microbial strain of the one or more microbial strains in the composition comprises at least about 10 1 , 5×10 1 , 10 2 , 5×10 2 , 10 3 , 5×10 3 , 10 4 , 5×10 4 , 10 5 , 5×10 5 , 10 6 , 5×10 6 , 10 7 , 5×10 7 , 10 8 , 5×10 8 , 10 9 , 5×10 9 , 10 10 , 5×10 10 , 10 11 , 5×10 11 , 10 12 In some embodiments, each of the one or more microbial strains in the composition comprises at most about 10 CFU or more. 15 , 5×10 14 , 10 14 , 5×10 13 , 10 13 , 5×10 12 , 10 12 , 5×10 11 , 10 11 , 5×10 10 , 10 10 , 5×10 9 , 10 9 , 5×10 8 , 10 8 In some embodiments, each microbial strain of the one or more microbial strains in the composition comprises the same number of CFU. In some embodiments, some microbial strains of the one or more microbial strains in the composition comprise different numbers of CFU.
[0017] The present disclosure provides, inter alia, compositions for use in treating a vagus nerve-related disease, disorder, or condition, comprising one or more microbial strains, components thereof, or metabolic products thereof. In some embodiments, the compositions described herein comprise one or more metabolic products (e.g., derived from a source other than the microbial strain (e.g., synthetically derived), and the compositions are for treating a vagus nerve-related disease, disorder, or condition.
[0018] The present disclosure provides a composition comprising one or more microbial strains selected from Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or combinations thereof. In some embodiments, the composition comprises one or more microbial strains selected from Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella atypica, Bifidobacterium sp., or combinations thereof. In some embodiments, the composition comprises a microbial strain. In some embodiments, the microbial strain is Bacillus subtilis. In some embodiments, the composition comprises at least two microbial strains selected from the group consisting of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or combinations thereof. In some embodiments, the composition comprises at least two microbial strains selected from the group consisting of Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella atypica, Bifidobacterium sp., or combinations thereof.In some embodiments, the composition comprises at least five microbial strains selected from the group consisting of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or combinations thereof. In some embodiments, the composition comprises at least five microbial strains selected from the group consisting of Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella atypica, Bifidobacterium sp., or combinations thereof. In some embodiments, the composition comprises or consists of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp. In some embodiments, the composition comprises or consists of Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella atypica, Bifidobacterium sp.
[0019] In some embodiments, the compositions described herein include one or more metabolic products (e.g., derived from a source other than a microbial strain (e.g., synthetically derived)), and the composition is for treating a vagus nerve-related disease, disorder, or condition.
[0020] In some embodiments, the composition is for topical, oral, subcutaneous, intravenous, intramuscular, intracerebral, intrathecal, rectal, intraocular, intravitreal, or suprachoroidal administration. In some embodiments, the composition is for oral administration. In some embodiments, the composition is for intracerebral administration.
[0021] The present disclosure provides that the compositions described herein are for use in modulating one or more metabolic products in a subject.
[0022] The present disclosure provides that the compositions described herein are for use in regulating one or more characteristics in a subject.In some embodiments, the one or more characteristics are or include: (i) cell survival level, (ii) nucleic acid or protein level or activity, or its form, (iii) mitochondrial function, (iv) peroxisome function, (v) ATP level, (vi) proteasome function, (vii) lysosomal function, (viii) oxidative stress, (ix) inflammation, (x) nerve damage (e.g., due to beta amyloid, tangles, etc.), (xi) nerve fiber damage, (xii) nerve ending damage, or (xiii) brain damage.
[0023] The present disclosure provides that the compositions described herein are for uses characterized by the ability of one or more microbial strains to modulate one or more metabolic products in a subject.
[0024] The present disclosure provides that the use of the compositions described herein is for treating or ameliorating a disease, disorder, or condition in a subject, wherein the disease, disorder, or condition is associated with one or more metabolic products. The present disclosure further provides that the compositions described herein are for use in treating or preventing or ameliorating a vagus nerve-related disease, disorder, or condition, comprising one or more components or metabolic products, which may be selected from Appendix 1, Appendix 3, or Appendix 4. In some embodiments, the use of the compositions described herein is for treating or ameliorating a vagus nerve-related disease, disorder, or condition, as described herein. In some embodiments, the disease, disorder, or condition is AD, PD, ALS, autism spectrum disorder, rheumatoid arthritis, hypertension, heart failure, diabetes, arrhythmia, IBD, fatty liver disease, depression, epilepsy, bipolar disorder, anxiety, PTSD, MS, autoimmune disease, obesity, AP, eye disease including retinal ischemia / reperfusion (I / R) injury, COPD, mood disorders, migraine and cluster headaches, eating disorders, anorexia, psoriasis and psoriatic arthropathy, endocrine tumors and vagus nerve paraganglioma, heartburn, GERD, SIBO, IBS, celiac disease, chronic constipation, kidney disease, endometriosis, aging, or infertility including vascular disease. In some embodiments, the use comprises treating, reducing the risk of, ameliorating, or preventing one or more of the following, or a combination: nerve cell injury, nerve ending injury, nerve fiber injury, brain injury, vagus nerve-associated organ injury.
[0025] The present disclosure provides a method of screening microbial strains comprising contacting the microbial strain with a culture comprising a neuronal cell or neuronal cell line that models a vagus nerve-related disease, disorder, or condition, and determining whether the microbial strain alters a characteristic of the culture, wherein the characteristic is associated with the vagus nerve-related disease, disorder, or condition.
[0026] In some embodiments, the determining step comprises comparing the characteristic before and after performance of the contacting step, hi some embodiments, the determining step comprises comparing the characteristic to an equivalent reference after the contacting step.
[0027] In some embodiments, the comparable reference is a historical reference. In some embodiments, the comparable reference is a negative control reference. In some embodiments, the comparable reference is a positive control reference.
[0028] In some embodiments, the characteristic is a level of cell survival. In some embodiments, the characteristic is a level or activity of a nucleic acid or protein, or a form thereof. In some embodiments, the characteristic is or includes one or more of mitochondrial function, peroxisomal function, proteasomal function, or lysosomal function. In some embodiments, the characteristic is or includes inflammation. In some embodiments, the characteristic is or includes ATP levels. In some embodiments, the characteristic is or includes one or more of cell damage (e.g., neuronal). In some embodiments, the characteristic is or includes one or more of neuronal damage (e.g., due to beta amyloid, tangles, etc.), nerve fiber damage, nerve ending damage, or brain damage. In some embodiments, the characteristic is or includes oxidative stress.
[0029] In some embodiments, the microbial strain alters one or more characteristics of the culture. In some embodiments, the one or more characteristics are associated with a vagus nerve-related disease, disorder, or condition described herein. In some embodiments, the one or more characteristics are or include (i) levels of cell survival, (ii) levels or activities of nucleic acids or proteins, or forms thereof, (iii) mitochondrial function, (iv) peroxisome function, (v) ATP levels, (vi) proteasome function, (vii) lysosomal function, (viii) oxidative stress, (ix) inflammation, (x) nerve damage (e.g., due to beta-amyloid, tangles, etc.), (xi) nerve fiber damage, (xii) nerve ending damage, or (xiii) brain damage.
[0030] The present disclosure provides a method comprising administering a composition comprising one or more microbial strains, components thereof, or metabolites thereof to a subject in need thereof. In some embodiments, the present disclosure provides a method comprising administering a composition comprising one or more components or metabolites to a subject in need thereof. In some embodiments, the metabolites can be derived from one or more microbial strains. In some embodiments, the metabolites can be derived from a source that is not a microbial strain, e.g., synthetically produced.
[0031] In some embodiments, the microbial strain or metabolite has altered a characteristic of the subject. In some embodiments, the characteristic is a level of cell survival. In some embodiments, the characteristic is a level or activity of a nucleic acid or protein, or a form thereof. In some embodiments, the characteristic is or includes one or more of mitochondrial function, peroxisomal function, proteasomal function, or lysosomal function. In some embodiments, the characteristic is or includes inflammation. In some embodiments, the characteristic is or includes ATP levels. In some embodiments, the characteristic is or includes one or more of cell damage (e.g., neuronal). In some embodiments, the characteristic is or includes one or more of neuronal damage (e.g., due to beta amyloid, tangles, etc.), nerve fiber damage, nerve ending damage, or brain damage. In some embodiments, the characteristic is or includes oxidative stress.
[0032] In some embodiments, the microbial strain may alter one or more characteristics of a subject. In some embodiments, the one or more characteristics is or includes (i) levels of cell survival, (ii) levels or activities of nucleic acids or proteins or forms thereof, (iii) mitochondrial function, (iv) peroxisomal function, (v) ATP levels, (vi) proteasomal function, (vii) lysosomal function, (viii) oxidative stress, (ix) inflammation, (x) nerve damage (e.g., due to beta amyloid, tangles, etc.), (xi) nerve fiber damage, (xii) nerve ending damage, or (xiii) brain damage.
[0033] In some embodiments the characteristic is associated with a vagus nerve-related disease, disorder, or condition.
[0034] The present disclosure provides a method of characterizing a microbial strain comprising adding the microbial strain to a culture comprising a neuronal cell or neuronal cell line that models a vagus nerve-related disease, disorder, or condition, and determining whether the microbial strain affects the level of one or more characteristics of the neuronal cell or neuronal cell line, where the one or more characteristics are associated with the vagus nerve-related disease, disorder, or condition.
[0035] The present disclosure provides a method of manufacturing a pharmaceutical treatment comprising characterizing one or more microbial strains, components, or metabolites thereof, comprising the steps of adding one or more microbial strains to a culture comprising neuronal cells or neuronal cell lines that model a vagus nerve-related disease, disorder, or condition, and determining whether the one or more microbial strains affect the level of one or more characteristics of the neuronal cells or neuronal cell lines, where the one or more characteristics are associated with the vagus nerve-related disease, disorder, or condition.
[0036] The disclosure provides methods of producing pharmaceutical treatments that include adding one or more microbial strains, components, or metabolic products thereof (e.g., metabolic products derived from different sources (e.g., microbial strains, synthetic, etc.)) to a syrup, liquid, tablet, troche, gummy, capsule, powder, gel, film, injectable, or eye drop.
[0037] The present disclosure provides methods for evaluating a microbial strain for its ability to affect one or more characteristics of the culture, comprising adding the microbial strain to a culture comprising neuronal cells or neuronal cell lines that model a vagus nerve-related disease, disorder, or condition, and determining whether the microbial strain affects the level of one or more characteristics of the neuronal cells or neuronal cell lines, wherein the one or more characteristics are associated with the vagus nerve-related disease, disorder, or condition.
[0038] In some embodiments, the method further comprises determining a level of one or more characteristics of the neuronal cells or neuronal cell line in the culture prior to adding the microbial strain to the culture, determining a level of the same one or more characteristics of the neuronal cells or neuronal cell line in the culture after adding the microbial strain to the culture, and comparing the level of the one or more characteristics determined prior to adding the microbial strain to the level of the one or more characteristics determined after adding the microbial strain.
[0039] In some embodiments, the one or more characteristics include (i) level of cell viability, (ii) level or activity of a nucleic acid or protein, or a form thereof, (iii) mitochondrial function, (iv) peroxisomal function, (v) ATP levels, (vi) proteasome function, (vii) lysosomal function, (viii) oxidative stress, (ix) inflammation, (x) nerve damage (e.g., due to beta amyloid, tangles, etc.), (xi) nerve fiber damage, (xii) nerve ending damage, (xiii) brain damage, or (xiv) a combination thereof.
[0040] The present disclosure provides that the compositions described herein are for use in the treatment or prevention of a vagus nerve-related disease, disorder, or condition that includes one or more microbial strains, components thereof, or metabolic products thereof. In some embodiments, the compositions described herein are for use in the treatment or prevention of a vagus nerve-related disease, disorder, or condition that includes one or more metabolic products (e.g., derived from a source other than a microbial strain (e.g., synthetically derived)).
[0041] The present disclosure provides that the compositions described herein are for use in the treatment or prevention of a vagus nerve-related disease, disorder, or condition comprising one or more microbial strains, components thereof, or metabolites thereof, where the one or more components or metabolites (e.g., of the one or more microbial strains) are selected from Appendix 1, Appendix 3, or Appendix 4. The present disclosure further provides that the compositions described herein are for use in the treatment or prevention of a vagus nerve-related disease, disorder, or condition comprising one or more components or metabolites, which may be selected from Appendix 1, Appendix 3, or Appendix 4.
[0042] In some embodiments, the metabolites may be derived from one or more microbial strains. In some embodiments, the metabolites may be derived from a source that is not a microbial strain, e.g., synthetically produced. In some embodiments, the one or more components or metabolites (e.g., of one or more microbial strains) are bile acids. In some embodiments, the one or more components or metabolites (e.g., of one or more microbial strains) are tauroursodeoxycholic acid. In some embodiments, the one or more components or metabolites are butyrylcamitine, theobromine, p-hydroxyphenylpyruvic acid, propionic acid, picolinic acid, 2-hydroxy-4 methylvaleric acid, N6-acetylcysine, urocanic acid, N5-ethylglutamine, trigonelline, stachydrine, ectoine, 5-hydroxylysine, arginine (Arg), cholic acid, 2-(4-hydroxyphenyl)propionic acid, N-acetyltryptophan, hydroxyproline, argininosuccinic acid, glutamic acid (Glu), sarcosine, 5-methoxyindoleacetic acid, indole-3-lactic acid, isovalerylalanine, N-acetylleucine, 1-methylhistidine, N-acetylphenylalanine, proline (Pro), or any combination thereof.In some embodiments, the one or more components or metabolites are 4-hydroxyphenylpyruvate, ectoine, gramine, N-acetyl-L-phenylalanine, nepsilon-acetyl-L-lysine, stachydrine, trigonelline, 3-ureidopropionic acid, theobromine, hippuric acid, imidazolepropionic acid, NG-methyl-L-arginine, transurocanic acid, N-acetyl-L-leucine, sarcosine, isobutyrylcalcine, acetyl-L-phenylalan ... Nitine, b-Hydroxyisovaleric acid, L-Theanine / N5-Ethylglutamine, 5-Hydroxylysine, Phenaceturic acid, Betaine, Hydroxyproline, Picolinic acid, 2-Aminoadipic acid, Glycerophosphocholine, Carnitine, Glycerol 3-phosphate, Argininosuccinic acid, Creatine, Terephthalic acid, Homocitrulline, Mucic acid, Homocysteine sulfinic acid, Trimethyllysine, Spermidine, Glyoxylic acid, XA0013 C6H6O4S, 3-indoxyl sulfate, nicotinamide, N-formylglycine, ureidoglycolate, N-methylproline, glucaric acid, butyrylcarnitine, methionine sulfoxide, carboxymethyllysine, glycolic acid, phenaceturic acid, diethanolamine, phosphorylcholine, guanidinosuccinic acid, N-acetylhistidine, glyceric acid, S-methylmethionine, cysteine glutathione disulfide, kynurenine, N-acetylphenylalanine, threonic acid, malic acid, 7,8-dihydrobiopterin, homovanillic acid, taurocholic acid, 5-methoxyindoleacetic acid, butyrate, b-hydroxyisovaleric acid, 2-oxoglutaric acid, N-acetyltryptophan, thiaproline, hypotaurine, cholic acid, acetoacetic acid, ethanolamine, guanidoacetic acid, S-sulfocysteine, myristic acid C14:0 XA0027, or any combination thereof.
[0043] In some embodiments, the compositions described herein are for use in treating or preventing vagus nerve-related diseases, disorders, or conditions, including one or more microbial strains, components thereof, or metabolites thereof. In some embodiments, the compositions described herein are for use in treating, reducing the risk of, ameliorating, or preventing one or more of the following, or a combination: nerve cell injury, nerve ending injury, nerve fiber injury, brain injury, vagus nerve-related organ injury.
[0044] In some embodiments, the composition comprises one or more microbial strains selected from Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or combinations thereof. In some embodiments, the composition described herein is for the use described herein and comprises one or more microbial strains selected from Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella atypica, Bifidobacterium sp., or combinations thereof. In some embodiments, the composition described herein is for the use described herein and comprises a microbial strain. In some embodiments, the composition described herein is for the use described herein and the microbial strain is Bacillus subtilis. In some embodiments, the compositions described herein are for the uses described herein and comprise at least two microbial strains selected from the group consisting of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or combinations thereof.In some embodiments, the compositions described herein are for the uses described herein and comprise at least two microbial strains selected from the group consisting of Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella atypica, Bifidobacterium sp., or combinations thereof. In some embodiments, the compositions described herein are for the uses described herein and comprise at least five microbial strains selected from the group consisting of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or combinations thereof. In some embodiments, the compositions described herein are for the uses described herein and comprise at least five microbial strains selected from the group consisting of Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella atypica, Bifidobacterium sp., or combinations thereof.In some embodiments, the compositions described herein are for the uses described herein and comprise or consist of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp. In some embodiments, the compositions described herein are for the uses described herein and comprise or consist of Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella atypica, Bifidobacterium.
[0045] The present disclosure provides an injectable comprising a composition described herein.
[0046] The present disclosure provides dietary supplements comprising the compositions described herein.
[0047] The present disclosure provides kits comprising the compositions described herein for use in treating or preventing a vagus nerve-related disease, disorder, or condition.
[0048] These and other aspects encompassed by the present disclosure are described in more detail below and in the claims.
[0049] definition The scope of the present invention is defined by the claims attached hereto, and is not limited by any particular embodiment described herein. Those skilled in the art will recognize, upon reading this specification, various modifications that may be equivalent to such described embodiments or otherwise fall within the scope of the claims. Generally, terms used herein follow their understood meanings within the art, unless expressly indicated otherwise. Explicit definitions of certain terms are provided below, and the meaning of these and other terms in specific instances throughout this specification will be clear to those skilled in the art from the context.
[0050] The use of ordinal terms such as "first," "second," "third," etc. in the claims to modify claim elements does not, in itself, convey any priority, precedence, or ordering of the elements of one claim relative to another claim, or the temporal order in which acts of a method are performed, but is merely used as a label to distinguish the elements of a claim within one claim having a particular name from elements within another claim having the same name (in the absence of the use of the ordinal terminology).
[0051] The articles "a" and "an" as used herein should be understood to include plural referents unless clearly indicated to the contrary. A claim or description including "or" between one or more members of a group is considered satisfied if one, more than one, or all of the members of the group are present in, employed in, or otherwise relevant to a given product or process, unless clearly indicated to the contrary or otherwise evident from the context. In some embodiments, exactly one member of a group is present in, employed in, or otherwise relevant to a given product or process. In some embodiments, more than one or all members of a group are present in, employed in, or otherwise relevant to a given product or process. It should be understood that the present invention encompasses all modifications, combinations, and permutations of one or more limitations, elements, clauses, descriptive terms, etc. from one or more of the enumerated claims that are introduced into another claim that is dependent on the same base claim (or any other claim, if relevant), unless otherwise indicated or unless it would be apparent to one of ordinary skill in the art that a contradiction or inconsistency would result. When elements are presented as a list (e.g., in a Markush group or similar format), it is understood that each subgroup of elements is also disclosed, and any element(s) can be removed from the group. In general, when an embodiment or aspect is referred to as "comprising" certain elements, features, etc., it should be understood that a particular embodiment or aspect "consists" or "consists essentially of" such elements, features, etc. For purposes of brevity, the embodiments have not been specifically described in so many words in all instances herein. It should also be understood that any embodiment or aspect may be expressly excluded from the claims, regardless of whether a specific exclusion is described herein.
[0052] Administration: As used herein, the term "administration" typically refers to administration of a composition to a subject or system to achieve delivery of the agent to the subject or system. In some embodiments, the agent is or is included in a composition, and in some embodiments, the agent is produced through metabolism of the composition or one or more components thereof. Those skilled in the art will recognize various routes that may be utilized for administration to a subject, e.g., a human, in the appropriate circumstances. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, etc. In some specific embodiments, administration may be bronchial (e.g., by intratracheal instillation), oral, dermal (e.g., may be or include one or more of topical to the dermis, intradermal, interdermal, transdermal, etc.), enteral, intraarterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, in a specific organ (e.g., intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, vitreous, etc. In many embodiments provided by the present disclosure, administration is oral administration. In some embodiments, administration may involve only a single dose. In some embodiments, administration may involve application of a fixed number of doses. In some embodiments, administration may involve administration that is intermittent (e.g., multiple doses separated in time) and / or periodic (e.g., individual doses separated by a common period of time) administration. In some embodiments, administration may involve continuous administration (e.g., perfusion) for at least a selected period of time. Administration of cells may be by any suitable route that results in delivery to a desired location in a subject, where at least a portion of the delivered cells or components of cells remain viable. The period of survival of cells after administration to a subject may be as short as a few hours, e.g., 24 hours, to as long as days or years, i.e., long-term engraftment. In some embodiments, administration involves delivery of a bacterial extract or preparation that includes one or more bacterial metabolic products and / or by-products, but is completely devoid of viable bacterial cells.
[0053] Analog: As used herein, the term "analog" refers to a substance that shares one or more specific structural features, elements, components, or moieties with a reference substance. Typically, an "analog" exhibits significant structural similarity with the reference substance, e.g., sharing a core or consensus structure, but differs in certain individual respects. In some embodiments, an analog is a substance that can be generated from a reference substance, e.g., by chemical manipulation of the reference substance. In some embodiments, an analog is a substance that can be generated through the implementation of a synthetic process that is substantially similar (e.g., shares multiple steps) to that which generates the reference substance. In some embodiments, an analog is generated or can be generated through the implementation of a synthetic process that is different from that used to generate the reference substance.
[0054] Approximately: When applied to one or more values of interest, includes values that are similar to a stated reference value. In certain embodiments, the term "approximately" or "about" refers to a range of values that are within ±10% (more or less) of a stated reference value, unless otherwise stated or otherwise clear from the context (except where such number exceeds 100% of the possible values).
[0055] Equivalent: As used herein, the term "equivalent" refers to two or more agents, entities, situations, sets of conditions, subjects, etc. that may not be identical to each other, but are sufficiently similar to allow comparisons between them, so that a person skilled in the art will understand that conclusions can be reasonably drawn based on observed differences or similarities. In some embodiments, equivalent sets of conditions, situations, individuals, or populations are characterized by a number of substantially identical characteristics and one or a few altered characteristics. A person skilled in the art will understand what degree of identity is required in any given situation for two or more such agents, entities, situations, sets of conditions, etc. to be considered equivalent in context. For example, a person skilled in the art will understand that sets of situations, individuals, or populations are equivalent to each other when they are characterized by a sufficient number and type of substantially identical characteristics to warrant a reasonable conclusion that the results obtained under or with the different sets of situations, individuals, or populations, or the differences in the observed phenomena, are caused by or indicate variations in the characteristics that are diverse.
[0056] Conservative: As used herein, refers to the case when describing a conservative amino acid substitution, which involves the replacement of an amino acid residue with another amino acid residue having a side chain R group with similar chemical properties (e.g., charge or hydrophobicity). Generally, a conservative amino acid substitution does not substantially change the desired functional property of a protein, e.g., the ability of a receptor to bind a ligand. Examples of groups of amino acids having side chains with similar chemical properties include aliphatic side chains such as glycine (Gly, G), alanine (Ala, A), valine (Val, V), leucine (Leu, L), and isoleucine (Ile, I); aliphatic hydroxyl side chains such as serine (Ser, S) and threonine (Thr, T); amide-containing side chains such as asparagine (Asn, N) and glutamine (Gln, Q); aromatic side chains such as phenylalanine (Phe, F), tyrosine (Tyr, Y), and tryptophan (Trp, W); basic side chains such as lysine (Lys, K), arginine (Arg, R), and histidine (His, H); acidic side chains such as aspartic acid (Asp, D) and glutamic acid (Glu, E); and sulfate-containing side chains such as cysteine (Cys, C) and methionine (Met, M). Conservative amino acid substitutions include, for example, valine / leucine / isoleucine (Val / Leu / Ile, V / L / I), phenylalanine / tyrosine (Phe / Tyr, F / Y), lysine / arginine (Lys / Arg, K / R), alanine / valine (Ala / Val, A / V), glutamate / aspartate (Glu / Asp, E / D), and asparagine / glutamine (Asn / Gln, N / Q). In some embodiments, a conservative amino acid substitution can be the substitution of any naturally occurring residue in a protein with alanine, for example, as used in alanine scanning mutagenesis. In some embodiments, conservative substitutions are made that have a positive value in the PAM250 log-likelihood matrix, as disclosed in Gonnet, GH et al., 1992, Science 256:1443-1445, which is incorporated herein by reference in its entirety. In some embodiments, the substitutions are reasonably conservative substitutions, and the substitutions have non-negative values in the PAM250 log-likelihood matrix. [Table 1]
[0057] Control: as used herein refers to the art-understood meaning of "control," which is a standard against which results are compared. Typically, a control is used to enhance the integrity of an experiment by isolating a variable in order to make conclusions about such a variable. In some embodiments, a control is a reaction or assay that is performed simultaneously with a test reaction or assay to provide a comparison target. "Control" also includes "control animals." A "control animal" can have a modification described herein, a different modification described herein, or no modification (i.e., a wild-type animal). In one experiment, the "test" (i.e., the variable being tested) is applied. In a second experiment, the "control," the variable being tested, is not applied. In some embodiments, a control is a historical control (i.e., a control of a previously performed test or assay, or a previously known amount or result). In some embodiments, a control is or includes a printed or otherwise kept record. A control can be a positive or negative control.
[0058] Determining, Measuring, Evaluating, Assessing, Assaying, and Analyzing: Determining, measuring, evaluating, assessing, assaying, and analyzing are used interchangeably herein to refer to any form of measurement, including determining whether an element is present. These terms include both quantitative and / or qualitative determinations. Assaying can be relative or absolute. "Assaying for the presence of" can be determining the amount of something present and / or determining whether it is present or absent.
[0059] Dosage form: Those skilled in the art will understand that the term "dosage form" may be used to refer to a physically discrete unit of an agent (e.g., a therapeutic agent) for administration to a subject. Typically, each such unit contains a predetermined amount of the agent. In some embodiments, such an amount is a unit dosage (or a whole fraction thereof) appropriate for administration according to a dosing regimen that has been determined to correlate with a desired or beneficial outcome when administered to a relevant population (i.e., in a therapeutic dosing regimen). Those skilled in the art will understand that the total amount of a therapeutic composition or agent to be administered to a particular subject is determined by one or more attending physicians and may involve administration of multiple dosage forms.
[0060] Dosage regimen: Those skilled in the art will understand that the term "dosage regimen" may be used to refer to a set of unit doses (typically more than one) administered individually to a subject, typically separated by a period of time. In some embodiments, a given drug has a recommended dosing regimen that may involve one or more doses. In some embodiments, the dosing regimen includes multiple doses, each of which is separated in time from the other doses. In some embodiments, the individual doses are separated from each other by periods of the same length, and in some embodiments, the dosing regimen includes multiple doses, and at least two different periods separating the individual doses. In some embodiments, all doses in the dosing regimen are the same unit dose amount. In some embodiments, different doses in the dosing regimen are different amounts. In some embodiments, the dosing regimen includes a first dose in a first dose amount, followed by one or more additional doses in a second dose amount that is different from the first dose amount. In some embodiments, the dosing regimen includes a first dose in a first dose amount, followed by one or more additional doses in a second dose amount that is the same as the first dose amount. In some embodiments, the dosing regimen correlates with a desired or beneficial outcome when administered across a relevant population.
[0061] Engineered: In general, the term "engineered" refers to the aspect of being manipulated by the hand of man. For example, a cell or organism is considered "engineered" when it has been manipulated such that its genetic information is changed (e.g., new genetic material not previously present is introduced, for example, by transformation, mating, somatic cell hybridization, transfection, transduction, or other mechanisms, or previously present genetic material is changed or removed, for example, by substitution or deletion mutations, or by mating protocols). As is common practice and understood by those skilled in the art, the progeny of an engineered polynucleotide or cell is typically still referred to as "engineered", despite the actual manipulation performed on the previous entity.
[0062] Excipient: as used herein refers to an inactive (e.g., non-therapeutic) agent that may be included in a pharmaceutical composition, for example, to provide or contribute to a desired consistency or stabilizing effect. In some embodiments, suitable pharmaceutical excipients may include, for example, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, nonfat dry milk, glycerol, propylene, glycol, water, ethanol, and the like.
[0063] Functional: As used herein, a "functional" biomolecule is a biomolecule in a form in which it exhibits the property and / or activity for which it is characterized. A biomolecule can have two functions (i.e., bifunctional) or many functions (i.e., multifunctional).
[0064] Gene: as used herein refers to a DNA sequence in a chromosome that codes for a product (e.g., an RNA product and / or a polypeptide product). In some embodiments, a gene includes coding sequences (i.e., sequences that code for a particular product). In some embodiments, a gene includes non-coding sequences. In some particular embodiments, a gene may include both coding (e.g., exon) and non-coding (e.g., intron) sequences. In some embodiments, a gene may include one or more regulatory sequences (e.g., promoters, enhancers, etc.) and / or intron sequences that may, for example, control or affect one or more aspects of gene expression (e.g., cell type specific expression, inducible expression, etc.). For purposes of clarity, it should be noted that the term "gene" as used in this disclosure generally refers to a portion of a nucleic acid that codes for a polypeptide or a fragment thereof, and that the term may optionally encompass regulatory sequences as will be clear to one of skill in the art from the context. This definition is not intended to exclude the application of the term "gene" to non-protein-coding expression units, but rather to clarify that in most cases, the term as used herein refers to a nucleic acid that codes for a polypeptide.
[0065] Improve, increase, enhance, inhibit, or reduce: As used herein, the terms "improve," "increase," "enhance," "inhibit," "reduce," or their grammatical equivalents, refer to a value that is relative to a baseline or other reference measurement. In some embodiments, the value is statistically significantly different from the baseline or other reference measurement. In some embodiments, a suitable reference measurement may be or include a measurement in a particular system (e.g., in a single individual) under otherwise comparable conditions in the absence (e.g., before and / or after) of a particular agent or treatment, or in the presence of a suitable comparable reference agent. In some embodiments, a suitable reference measurement may be or include a measurement in a comparable system that is known or expected to respond in a particular way in the presence of the relevant agent or treatment. In some embodiments, a suitable reference is a negative reference, and in some embodiments, a suitable reference is a positive reference.
[0066] Isolated: As used herein, refers to substances and / or entities that are (1) separated from at least some of the components with which they were originally produced (whether in nature and / or in an experimental setting) and / or (2) designed, produced, prepared, and / or manufactured by the hand of man. In some embodiments, isolated substances or entities may be concentrated, and in some embodiments, isolated substances or entities may be pure. In some embodiments, isolated substances and / or entities may be separated from about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or greater than about 99% of other components with which they were originally associated. In some embodiments, an isolated agent is about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is "pure" if it is substantially free of other components. In some embodiments, as will be understood by those skilled in the art, a substance may still be considered "enriched," "isolated," or "pure" after being combined with certain other components, such as, for example, one or more carriers or excipients (e.g., buffers, solvents, water, etc.), and in such embodiments, the isolation or purity rate of the substance is calculated without including such carriers or excipients. Those skilled in the art are aware of various techniques for isolating (e.g., concentrating or purifying) a substance or agent (e.g., using one or more of fractionation, extraction, precipitation, or other separation).
[0067] Level: As used herein, the term "level" refers to a scale of the amount or quantity of a substance (e.g., a metabolite). In some embodiments, the level may simply be the presence or absence of a substance. The level of a substance may be expressed in multiple ways or formats. For example, in some embodiments, the level is expressed as a percentage (%), a measure of weight (e.g., mg, μg, ng, etc.), a measure of concentration (e.g., mg / mL, μg / mL, ng / mL, etc.), a measure of volume (e.g., mL, μL, nL, etc.), % change, etc.
[0068] Metabolite: As used herein, the term "metabolite" refers to a substance (e.g., a small molecule, a macromolecule, an organic compound, or an inorganic compound) that is made or used during metabolism. Metabolism is generally understood as the process by which a substance (e.g., a food, a drug, a chemical, a cell, or a tissue) is chemically broken down. In some embodiments, a metabolite is an end product. In some embodiments, a metabolite is an intermediate. Exemplary metabolic products are provided herein, for example, in Appendices 1-1, 1-3, 3, and 4. Exemplary metabolic pathways are provided herein, for example, in Appendices 1-2.
[0069] Pharmaceutical composition: As used herein, the term "pharmaceutical composition" refers to a composition in which an active agent is formulated with one or more pharma- ceutically acceptable carriers. In some embodiments, the active agent is present in an amount of unit dose suitable for administration in a treatment regimen that exhibits a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, the pharmaceutical composition may be specially formulated for administration in solid or liquid form, including those adapted for intraocular, intravitreal, suprachoroidal, oral, subcutaneous, intravenous, intramuscular, intracerebral, intrathecal administration, e.g., drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., buccal, sublingual, and targeted for systemic absorption, boluses, powders, granules, pastes for application to the tongue, capsules, powders, and the like. In some embodiments, the active agent may be or include a cell or population of cells (e.g., a culture, e.g., of an ellagitanin-enzyme-synthesizing (EES) microorganism), and in some embodiments, the active agent may be an extract or component of a cell or population of cells (e.g., a culture). In some embodiments, the active agent may be or include a cell or population of cells (e.g., a culture, e.g., an ellagitannin enzyme synthesizing (EES) microorganism), and in some embodiments, the active agent may be or include an extract or component of a cell or population of cells (e.g., a culture). In some embodiments, the active agent may be or include an isolated, purified, or pure compound. In some embodiments, the active agent may have been synthesized in vitro (e.g., via chemical synthesis and / or enzymatic synthesis). In some embodiments, the active agent may be or include a natural product (whether isolated from its natural source or synthesized in vitro).
[0070] Pharmaceutically acceptable: As used herein, the term "pharmaceutical acceptable," which may be used, for example, in reference to a carrier, diluent, or excipient used to formulate a pharmaceutical composition disclosed herein, means the carrier, diluent, or excipient is compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
[0071] Pharmaceutically acceptable carrier: As used herein, the term "pharmaceutical acceptable carrier" refers to a pharma- ceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, that is involved in carrying or transporting the subject compounds from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the subject (e.g., patient). Some examples of materials which can function as pharma- ceutically acceptable carriers include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; excipients such as powdered tragacanth, malt, gelatin, talc, cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar-agar, buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, pH buffer solutions, polyesters, polycarbonates, and / or polyanhydrides, and other non-toxic compatible substances employed in pharmaceutical formulations.
[0072] Prebiotic: As used herein, "prebiotic" refers to an ingredient that enables or promotes specific changes in both composition and / or activity in the gastrointestinal microflora that may (or may not) confer a benefit to the host. In some embodiments, the prebiotic may include one or more of the following: The prebiotic includes pome fruit extract, berry extract, and walnut extract.
[0073] Prevention: The term "prevention" as used herein refers to a delay in the onset and / or a reduction in the frequency and / or severity of one or more symptoms of a particular disease, disorder, or condition. In some embodiments, prevention is assessed on a population basis such that an agent is considered to "prevent" a particular disease, disorder, or condition if a statistically significant reduction in the onset, frequency, and / or intensity of one or more symptoms of the disease, disorder, or condition is observed in a population susceptible to the disease, disorder, or condition. In some embodiments, prevention may be considered complete, for example, when the onset of a disease, disorder, or condition has been delayed for a predetermined period of time.
[0074] Reference: as used herein describes a standard or control against which a comparison is made. For example, in some embodiments, an agent, animal, individual, population, sample, sequence, or value of interest is compared to a reference or control agent, animal, individual, population, sample, sequence, or value. In some embodiments, the reference or control is tested and / or determined substantially simultaneously with the test or determination of interest. In some embodiments, the reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as will be understood by those of skill in the art, the reference or control is determined or characterized under conditions or circumstances equivalent to those being evaluated. Those of skill in the art will understand when sufficient similarity exists to justify reliance on and / or comparison to a particular potential reference or control. In some embodiments, the reference is a negative control reference, and in some embodiments, the reference is a positive control reference.
[0075] Risk: As understood from the context, "risk" of a disease, disorder, and / or condition refers to the likelihood that a particular individual will develop the disease, disorder, and / or condition. In some embodiments, the risk is expressed as a percentage. In some embodiments, the risk is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or up to 100%. In some embodiments, the risk is expressed relative to the risk associated with a reference sample or a group of reference samples. In some embodiments, the reference sample or a group of reference samples has a known risk of the disease, disorder, condition, and / or event. In some embodiments, the reference sample or a group of reference samples is derived from an individual comparable to the particular individual. In some embodiments, the relative risk is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more.
[0076] Sample: As used herein, the term "sample" typically refers to an aliquot of material obtained from or derived from a source of interest. In some embodiments, the source of interest is a biological or environmental source. In some embodiments, the source of interest may be or include a cell, or an organism such as a microorganism, a plant, or an animal (e.g., a human). In some embodiments, the source of interest is or includes a biological tissue or fluid. In some embodiments, the biological tissue or fluid may be or include amniotic fluid, aqueous humor, peritoneal fluid, bile, bone marrow, blood, breast milk, cerebrospinal fluid, earwax, chyle, chyme, ejaculate, endolymph, exudate, feces, gastric acid, gastric juice, lymph, mucus, pericardial fluid, perilymph, peritoneal fluid, pleural fluid, pus, catarrhal secretions, saliva, sebum, semen, serum, smegma, phlegm, synovial fluid, sweat, tears, urine, vaginal secretions, vitreous humor, vomit, plasma, mucus, digestive fluids, stool, and / or combinations or component(s) thereof. In some embodiments, the biological fluid may be or include intracellular fluid, extracellular fluid, intravascular fluid (plasma), interstitial fluid, lymph, and / or transcellular fluid. In some embodiments, the biological fluid may be or include phytoexudates. In some embodiments, the biological tissue or sample may be obtained, for example, by aspirate, biopsy (e.g., fine needle or tissue biopsy), swab (e.g., oral, nasal, skin, or vaginal swab), scraping, surgery, washing or lavage (e.g., bronchoalveolar epithelium, duct, nasal, ocular, oral, uterine, vaginal, or other washing or lavage). In some embodiments, the biological sample is or includes cells obtained from an individual. In some embodiments, the sample is a "primary sample" obtained directly from the source of interest by any suitable means. In some embodiments, as will be clear from the context, the term "sample" refers to a preparation obtained by processing the primary sample (e.g., by removing one or more components of the primary sample and / or by adding one or more agents to the primary sample), for example, by filtering using a semi-permeable membrane.Such a "processed sample" may include, for example, nucleic acids or proteins extracted from a sample or obtained by subjecting the primary sample to one or more techniques, such as amplification or reverse transcription of nucleic acids, isolation and / or purification of certain components, etc.
[0077] Small molecule: As used herein, the term "small molecule" refers to a small organic or inorganic molecule with a molecular weight below about 3,000 Daltons. Generally, a small molecule can have a molecular weight less than 3,000 Daltons (Da). The small molecule can be, for example, at least about 100 Da to about 3,000 Da (e.g., about 100 to about 3,000 Da, about 100 to about 2500 Da, about 100 to about 2,000 Da, about 100 to about 1,750 Da, about 100 to about 1,500 Da, about 100 to about 1,250 Da, about 100 to about 1,000 Da, about 100 to about 750 Da, about 100 to about 500 Da, about 200 to about 1500, about 500 to about 1000, about 300 to about 1000 Da, or about 100 to about 250 Da).
[0078] Subject: As used herein, the term "subject" refers to an individual to whom the provided treatment is administered. In some embodiments, the subject is an animal. In some embodiments, the subject is a mammal, for example, a mammal experiencing or susceptible to a disease, disorder, or condition described herein. In some embodiments, the animal is a vertebrate, for example, a mammal such as a non-human primate (especially a higher primate), sheep, dog, rodent (e.g., mouse or rat), guinea pig, goat, pig, cat, rabbit, or cow. In some embodiments, the animal is a non-mammal, such as a chicken, an amphibian, a reptile, or the invertebrate model C. elegans. In some embodiments, the subject is a human. In some embodiments, the subject is afflicted with or susceptible to one or more diseases, disorders, or conditions described herein. In some embodiments, the subject exhibits one or more symptoms of one or more diseases, disorders, or conditions described herein. In some embodiments, the subject has been diagnosed with one or more diseases, disorders, or conditions described herein. In some embodiments, the subject is undergoing or has undergone a particular treatment to diagnose and / or treat a disease, disorder, or condition, hi another embodiment, the subject is an experimental animal or surrogate animal as a disease model.
[0079] Substantially: As used herein, refers to a qualitative state of exhibiting the full or nearly full extent or degree of a desired characteristic or property. Those skilled in the biological arts will understand that biological and chemical phenomena rarely, if ever, proceed to completion and / or completeness or achieve or avoid absolute results. Thus, the term "substantially" is used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
[0080] Therapeutic regimen: "Therapeutic regimen," as that term is used herein, refers to a dosing regimen, the administration of which across a relevant population can be correlated with a desired or beneficial therapeutic outcome.
[0081] Therapeutically effective amount: as used herein, refers to the amount at which it is administered that produces a desired effect. In some embodiments, the term refers to an amount that is sufficient to treat a disease, disorder, and / or condition when administered to a population suffering from or susceptible to the disease, disorder, and / or condition according to a treatment regimen. In some embodiments, a therapeutically effective amount is an amount that reduces the incidence and / or severity and / or delays the onset of one or more symptoms of the disease, disorder, and / or condition. Those skilled in the art will appreciate that the term "therapeutically effective amount" does not actually require that successful treatment be achieved in a particular individual. Rather, a therapeutically effective amount may be an amount that, when administered to a subject (e.g., a patient) in need of such treatment, provides a particular desired pharmacological response in a significant number of subjects. In some embodiments, reference to a therapeutically effective amount may be a reference to an amount measured in one or more specific tissues (e.g., tissues affected by a disease, disorder, or condition) or fluids (e.g., blood, saliva, serum, sweat, tears, urine, etc.). One of skill in the art will appreciate that in some embodiments, a therapeutically effective amount of a particular agent or therapy may be formulated and / or administered in a single dose, hi some embodiments, a therapeutically effective agent may be formulated and / or administered in multiple doses, e.g., as part of a dosing regimen.
[0082] Treatment: As used herein, the term "treatment" (also "treat" or "treating") refers to any administration of a therapy that partially or completely relieves, ameliorates, alleviates, inhibits, delays the onset, reduces the severity, and / or reduces the incidence of one or more symptoms, characteristics, and / or causes of a particular disease, disorder, and / or condition. In some embodiments, such treatment may be treatment of a subject who does not show signs of the relevant disease, disorder, and / or condition and / or a subject who shows only early signs of the disease, disorder, and / or condition. Alternatively, or in addition, such treatment may be treatment of a subject who shows one or more established signs of the relevant disease, disorder, and / or condition. In some embodiments, the treatment may be treatment of a subject who has been diagnosed as suffering from the relevant disease, disorder, and / or condition. In some embodiments, the treatment may be treatment of a subject who is known to have one or more susceptibility factors that are statistically correlated with an increased risk of developing the relevant disease, disorder, and / or condition. [Brief description of the drawings]
[0083] [Figure 1] A schematic diagram of the brain-vagus-microbiota axis, in other words the communication between the central nervous system and the microbiota through the vagus nerve, is shown. The afferent fibers of the vagus nerve can be stimulated by microbiota components either directly or indirectly via enteroendocrine cells (GECs). Figure 1 was taken from the review article Bonaz B., Bazin T. and Pellissier S. (2018) The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. Front. Neurosci. 12:49. doi:10.3389 / fnins.2018.00049. [Figure 2A] 1 shows cytokine levels for eight (8) different cytokines in human monocytes upon treatment with various metabolites and controls. [Figure 2B]1 shows cytokine levels for eight (8) different cytokines in human monocytes upon treatment with various metabolites and controls. [Figure 2C] 1 shows cytokine levels for eight (8) different cytokines in human monocytes upon treatment with various metabolites and controls. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0084] Vagus Nerve and Related Diseases, Disorders, and Conditions The vagus nerve, a key component of the autonomic nervous system and the 10th cranial nerve, regulates, among other things, the brain-gut axis (i.e., bidirectional interactions between the brain and the gut, see Figure 1). The vagus nerve is a mixed nerve with 4 / 5 afferent fibers and 1 / 5 efferent fibers. The vagus nerve connects to almost every major organ in the body and oversees a wide range of important functions. It carries information in both directions between the brain and the internal organs, acting as a kind of super-communication highway. It connects, among other things, to the ears, larynx, larynx, esophagus, lungs, trachea, heart, aorta, kidneys, pancreas, portal vein, biliary system, spleen, bladder, adrenal glands, as well as most of the digestive tract, including the liver, esophagus, stomach, and most of the intestine. The vagus nerve is involved in activities that regulate immunity, metabolism, and inflammation, among other things. For example, the cholinergic anti-inflammatory pathway (CAP) is a neuroimmune pathway that is activated by vagus nerve stimulation. Signals from the vagus nerve are transmitted to immune cells in the spleen, inducing a series of responses that release the neurotransmitters norepinephrine and acetylcholine, reduce proinflammatory cytokines, and attenuate inflammation.In another example, action potentials originating from the vagus nerve regulate T cells, which in turn produce the neurotransmitter acetylcholine, which is necessary to control the innate immune response. Given the extensive connections of the vagus nerve with various organs in the body, vagus nerve dysfunction is suspected in many diseases such as Alzheimer's disease, Parkinson's disease, ALS, autism spectrum disorder, rheumatoid arthritis, hypertension, heart failure, diabetes, arrhythmias, IBD, fatty liver disease, depression, epilepsy, bipolar disorder, anxiety, PTSD, MS, autoimmune diseases, obesity, AP, eye diseases including retinal ischemia / reperfusion (I / R) injury, COPD, mood disorders, migraine and cluster headaches, eating disorders, anorexia, psoriasis and psoriatic arthropathy, endocrine tumors and vagal paragangliomas, heartburn, GERD, SIBO, IBS, celiac disease, chronic constipation, kidney disease, endometriosis, aging, or infertility including vascular diseases.
[0085] Because the vagus nerve is the conduit that connects organs to the brain and carries signals between them, if one or more of the major components of this system (i) one or more organs, (ii) nerve endings, (iii) nerve fibers, and (iv) the brain are not functioning as expected, then the end-to-end process between the various such connecting organs and the brain via the vagus nerve is not functioning optimally. Any one or more of these four major components may be partially defective (i.e., not functioning as expected, dysfunctional, or underperforming), examples of which include, but are not limited to, the following: i. One or more defective organs may provide erroneous information to their local vagus nerve endings, which are then transmitted via nerve fibers to the brain. ii. Damaged nerve endings can provide erroneous signals even when the nerve fiber is functioning normally. For example, chronic exposure to toxins can cause such damage. iii. The cells that make up defective / damaged nerve fibers, e.g., vagus nerve fibers, may have one or more of suboptimal mitochondrial, lysosomal, proteasomal, and peroxisome functions. In some embodiments, the cells that make up defective / damaged nerve fibers, e.g., vagus nerve fibers, may have one or more cellular components, such as suboptimal Golgi apparatus, ribosomes, etc. Such reduced cellular functions may also result in distorted signal delivery as described above, even when the nerve endings, the respective connecting organs, and the brain are healthy. Chronic inflammation of nerve fibers is another factor that may damage the underlying cells resulting in distorted signal transmission. Furthermore, persistent mis-distribution or distortion of control signals sent by the brain may also impair nerve fibers. iv. The brain, which is damaged by vagus nerve ending errors, beta amyloid, tangles, or other nerve damage, may also misinterpret the received signal or provide inappropriate regulatory signals to the connected organs. For example, mistransmitted signals from the brain to organs may play a role in cytokine storms. In other cases, one or more metabolic products from malignant microorganisms may cross the blood-brain barrier (BBB) and lead to chronic neuroinflammation. Furthermore, persistent or frequent distorted signals received by the brain via the vagus nerve may also increase neuroinflammation and / or lead to cognitive impairment.
[0086] Such a suboptimal system would manifest as a reduction in vagus nerve signaling effectiveness, expressed in terms of signal characteristics such as signal frequency, amplitude, phase, duration, polarization, and shape, among others. Other characteristics include signal strength, energy delivered, power delivered, etc. Some examples include: i. Either amplifying the signal when it is not needed, or attenuating it unnecessarily ii. The delivered signal may be amplified and the amplified signal is outside the operating band. iii. Drop the signal altogether iv. The frequency of the signal may be slower or faster than normal or may be outside the expected operating band v. The phase of the signal may be distorted vi. Polarization may be different than expected vii. The range between the minimum and maximum values of any of the characteristics is expanded or contracted. viii. Signal strength, expressed as the amount of energy delivered, may be higher or lower than normal ix. Signal power, such as signal ramp-up or downtime, may differ from normal x. Confusing signals with no discernible pattern xi. Mis-transmission of signals without obvious cause xii. Partial blockage or distortion of the signal xiii. The spacing between signals may be defective xiv. Nerve fibers that provide adjacent but conflicting signals xv. Nerve endings that are close together but provide conflicting signals xvi. A combination of one or more of the above
[0087] In short, signals traveling along the vagus nerve may be distorted at the point of origin, along the nerve fiber, or at the receiving end, and such distorted signals, if persisted over time, will at best result in suboptimal or at worst damaging effects.
[0088] Any of the above may lead to chronic inflammation; regulation of the nerves, the vagus nerve, or one or more organs connected to the vagus nerve, and suboptimal immune regulation, thus further adversely affecting the function of various organs, including all four major system components mentioned above. This condition then manifests as various diseases, forming a vicious cycle.
[0089] Signals traveling through the vagus nerve are reported to the brain to predict a certain corresponding composition of blood. Any form of poor quality signal can result in predictions that may be inconsistent or incorrect than should be reported.
[0090] Microbial preparation(s) and / or component(s) The present disclosure provides systems and methods comprising certain microorganisms and their metabolic products that can function in the following ways to improve the function of one or more key components of the systems described herein (e.g., the vagus nervous system): i. Improve the function of one or more organs by improving basic cellular function and appropriately promoting inflammatory, metabolic, and immune regulation ii. Improving cells containing nerve endings in a similar manner, thereby enhancing the quality of sensing and delivery of control signals; iii. strengthening (restoring functionality (e.g., fully or partially)) the cells that form nerve fibers and / or reducing their inflammation, thus improving the quality of communication through each such fiber; and iv. Significantly restores cellular level function in the brain, reducing neuroinflammation and improving the quality of signals emitted by the brain and the interpretation of signals received by it.
[0091] These enhanced functions of key components across several dimensions provide an end-to-end process improvement that results in an overall healthier component with, among other benefits, improved regulation of inflammation and immunity at the organ level, healthier cellular level function, a healthier vagus nerve, reduced vagal inflammation, and reduced neuroinflammation, thus creating a virtuous cycle.
[0092] The present disclosure provides systems and methods for evaluating, characterizing, and identifying one or more microbial strains of a microbiota (e.g., for improving the function of one or more key components of the vagus nerve system described herein). For example, the present disclosure provides systems and methods for evaluating, characterizing, and identifying one or more microbial strains of a microbiota having one or more capabilities. Such systems and methods may be useful for evaluating, characterizing, and identifying one or more microbial strains that affect the health of humans, livestock, and / or pets. In some embodiments, the one or more microbial strains affect the health of humans, livestock, and / or pets by modulating their respective metabolomes, cell viability, ATP levels, one or more other parameters or characteristics (e.g., of an organ of interest), or a combination thereof, to prevent, treat, or reduce the risk of a disease, disorder, or condition (e.g., associated with the vagus nerve). For example, the technology described herein may result in modulation of the subject's metabolome, improved cell survival, increased ATP levels, one or more other parameters or characteristics (e.g., levels of cell survival, nucleic acid or protein levels or activity or morphology thereof, mitochondrial function, peroxisomal function, ATP levels, proteasomal function, lysosomal function, oxidative stress, inflammation, neuronal damage (e.g., due to beta amyloid, tangles, etc.), nerve fiber damage, nerve ending damage, brain damage, etc.), or combinations thereof, which results in a decrease in the production of toxic components and / or components that are indicative of or are markers of cellular damage in the subject (e.g., in the subject's blood) (e.g., increased blood levels of neurofilament light chain protein (NF-L)).
[0093] The present disclosure also provides systems and methods for producing pharmaceutical compositions that include evaluating, characterizing, and identifying one or more microbial strains of a microbiota.
[0094] In some embodiments, the method includes evaluating, characterizing, and identifying one or more microbial strains from a snake, lizard, fish, or bird microbiota. In some embodiments, the method includes evaluating, characterizing, and identifying one or more microbial strains from a mammalian microbiota. The mammalian microbiota can be a canine, feline, equine, bovine, ovine, caprine, or porcine microbiota. In some embodiments, the microbiota used in the system or method described herein can prevent or treat a disease or condition.
[0095] Microbiota can be isolated from any system or tissue of an organism that supports microbial growth. For example, the microbiota can be skin microbiota, oral microbiota, nasal microbiota, gastrointestinal microbiota, brain microbiota, lung microbiota, or urogenital microbiota. A list of exemplary microbial strains found in gastrointestinal microbiota is included in Table 1 below. Microbiota samples can be obtained by various methods. For example, skin, oral, nasal, lung, or urogenital microbiota samples can be obtained using swabs or tissue scrapes. In some embodiments, gastrointestinal microbiota can be sampled from feces. Skin microbiota, oral microbiota, nasal microbiota, gastrointestinal microbiota, brain microbiota, lung microbiota, or urogenital microbiota samples can be obtained via biopsy.
[0096] In some embodiments, the microbiota is the microbiota of a healthy individual or an individual who does not suffer from or is not at risk of developing a particular disease or disorder.In some embodiments, the microbiota is the microbiota of an individual who suffers from or is at risk of developing a particular disease, disorder, or condition.In some embodiments, the microbiota is the microbiota of an individual who is known to suffer from a particular disease, disorder, or condition.In some embodiments, the human microbiota is the microbiota of a human who has an unknown risk of one or more diseases, disorders, or conditions.
[0097] In some embodiments, the microbiota is a reference microbiota. The reference microbiota may be the microbiota of a healthy individual or an individual who is not suffering from or at risk of developing a particular disease, disorder, or condition. In some cases, the reference microbiota may be derived from the same individual as the microbiota to be evaluated or characterized, but obtained at a different time. In some cases, the reference microbiota may be derived from the same individual as the microbiota to be evaluated or characterized, but obtained from a different system or tissue.
[0098] In some embodiments, individual microbial strains or combinations of microbial strains may be evaluated, characterized, or identified in relative abundance that differs from that of one or more such strains found in the microbiota. For example, the effect of modulating a cell or organism in response to a single strain may be evaluated, characterized, or identified using in vitro methods (e.g., mammalian cells) or in vivo methods using a mammal (e.g., mouse, human, etc.) described herein. In some embodiments, the effect of modulating a cell or organism to treat, prevent, or reduce the risk of, for example, a disease, disorder, or condition (e.g., a vagus nerve-related disease, disorder, or condition described herein) may be evaluated, characterized, or identified using in vitro methods (e.g., mammalian cells) or in vivo methods using a mammal (e.g., mouse, human, etc.) described herein. In some embodiments, the effect of modulating a cell or organism to treat, prevent, or reduce the risk of a disease, disorder, or condition (e.g., a vagus nerve-related disease, disorder, or condition described herein) by modulating, for example, one or more metabolic products of the cell or organism, one or more characteristics or parameters of the cell or organism (e.g., levels of cell survival, levels or activity of nucleic acids or proteins or their morphology, mitochondrial function, peroxisomal function, ATP levels, proteasomal function, lysosomal function, oxidative stress, inflammation, nerve damage (e.g., due to beta amyloid, tangles, etc.), nerve fiber damage, nerve ending damage, brain damage, etc.), or a combination thereof, may be assessed, characterized, or identified using in vitro methods (e.g., mammalian cells) or in vivo methods using mammals (e.g., mice, humans, etc.) described herein. As another example, the effect of modulating a cell or organism's (e.g., the level of one or more metabolites) in response to two microbial strains may be assessed, characterized, or identified together using the methods described herein to treat, prevent, or reduce the risk of a disease, disorder, or condition described herein.
[0099] Microbial strain extracts, components, or compounds can also be evaluated, characterized, or identified together using the methods described herein. In some cases, microbial strain extracts, components, or compounds that are determined to treat, prevent, or reduce the risk of disease, disorder, or condition in organisms (e.g., mammals) described herein can be evaluated, characterized, or identified. Evaluating, characterizing, or identifying microbial strain extracts, components, or compounds that treat, prevent, or reduce the risk of disease, disorder, or condition in organisms (e.g., mammals) can provide additional information about potential biomarkers, targets, or protective agents in microbiota.
[0100] A variety of techniques can be used to prepare extracts of microbial strains and / or to isolate or process extracts, components, or compounds therefrom (e.g., to isolate and / or purify one or more components or compounds therefrom). To name just a few, such techniques can include, for example, one or more of organic extraction, vacuum concentration, chromatography, etc.
[0101] Biological effects assessment The present disclosure provides insight that the compositions (e.g., microbiota compositions) described herein can be used to treat, prevent, and / or reduce the risk of a disease, disorder, or condition in an organism (e.g., a mammal (e.g., a human)) by contacting the organism with the composition(s) (e.g., feeding the composition to the organism, administering to the organism). In some embodiments, the organism can be afflicted with or at risk of a disease, disorder, or condition (e.g., a mammalian disease, disorder, or condition). To determine whether one or more compositions treat, prevent, or reduce the risk of a disease, disorder, or condition (e.g., a vagus nerve-related disease, disorder, or condition), the level of one or more metabolites can be observed, measured, or evaluated in a sample contacted with one or more compositions. For example, the level of one or more metabolites can be observed, measured, or evaluated in a sample at different times (e.g., before administration of the composition, after administration of the composition, during administration of the composition, etc.). To determine whether one or more compositions treat, prevent, or reduce the risk of a disease, disorder, or condition (e.g., a vagus nerve-related disease, disorder, or condition), one or more characteristics or parameters can be observed, measured, or evaluated in a sample contacted with one or more compositions. For example, one or more characteristics or parameters can be observed, measured, or evaluated in a sample at different times (e.g., before administration of the composition, after administration of the composition, during administration of the composition, etc.).
[0102] In some embodiments, the methods described herein utilize a first sample and a second sample. In some embodiments, the first sample is a reference sample. In some embodiments, the reference sample may be a sample obtained from a subject contacted with (e.g., administered or provided with) a composition, e.g., a CT10 composition, a CT6 composition, or a CT6m composition. In some embodiments, the reference sample may be a sample obtained from a subject contacted with (e.g., administered or provided with) a composition, e.g., a CT10 composition, a CT6 composition, or a CT6m composition, at a first time point. In some embodiments, the reference sample may be a sample obtained from a subject before contacting (e.g., administered or provided with) a composition, e.g., a CT10 composition, a CT6 composition, or a CT6m composition. In some embodiments, the reference sample may be a sample obtained from a healthy individual. In some embodiments, the reference sample may be a sample obtained from an individual who may be suffering from or at risk for a disease, disorder, or condition (e.g., a vagus nerve-related disease, disorder, or condition). In some embodiments, the reference sample is a control sample. In some embodiments, the reference sample is a negative control sample. In some embodiments, the reference sample is a positive control sample. In some embodiments, the reference sample can be a historical reference (e.g., a value across a control sample). In some embodiments, the reference sample can be from a printed publication (e.g., a textbook, a journal, etc.).
[0103] In some embodiments, the second sample may be a test sample. In some embodiments, the test sample may be a sample obtained from a subject contacted with (e.g., administered or provided with) a composition, such as a CT10 composition, a CT6 composition, or a CT6m composition. In some cases, the subject (e.g., a patient or a population) may be suffering from or at risk of a disease, disorder, or condition (e.g., a vagus nerve-related disease, disorder, or condition). In some cases, the subject (e.g., a patient or a population) may have an unknown risk of one or more diseases, disorders, or conditions described herein. In some embodiments, the test may be a sample obtained from a subject contacted with (e.g., administered or provided with) a composition, such as a CT10 composition, a CT6 composition, or a CT6m composition, at a second time point.
[0104] In some embodiments, the methods described herein include comparing one or more metabolite levels (e.g., metabolome), or one or more metabolite (e.g., metabolome) levels to one or more parameters or characteristics obtained from a test sample (e.g., level of cell survival, level or activity of nucleic acid or protein, or morphology thereof, mitochondrial function, peroxisome function, ATP levels, proteasome function, lysosomal function, oxidative stress, inflammation, neuronal damage (e.g., due to beta amyloid, tangles, etc.), nerve fiber damage, nerve ending damage, brain damage, etc.) or one or more parameters or characteristics obtained from a reference sample (e.g., level of cell survival, level or activity of nucleic acid or protein, or morphology thereof, mitochondrial function, peroxisome function, ATP levels, proteasome function, lysosomal function, oxidative stress, inflammation, neuronal damage (e.g., due to beta amyloid, tangles, etc.), nerve fiber damage, nerve ending damage, brain damage, etc.). In some embodiments, by comparing one or more metabolite levels, parameters, or characteristics obtained from a test sample with one or more metabolite levels, parameters, or characteristics obtained from a reference sample, a composition described herein can be evaluated, characterized, or identified as useful for treating, preventing, or reducing the risk of a disease, disorder, or condition described herein (e.g., a vagus nerve-related disease, disorder, or condition). In some embodiments, by comparing one or more metabolite levels, parameters, or characteristics obtained from a test sample with one or more metabolite levels, parameters, or characteristics obtained from a reference sample, it can be determined that a composition disclosed herein increases the severity or incidence of a disease, disorder, or condition phenotype. In some embodiments, by comparing one or more metabolite levels, parameters, or characteristics obtained from a test sample with one or more metabolite levels, parameters, or characteristics obtained from a reference sample, it can be determined that a composition disclosed herein reduces the severity or incidence of a disease, disorder, or condition phenotype.In some embodiments, by comparing one or more metabolite levels, parameters, or characteristics obtained from a test sample with one or more metabolite levels, parameters, or characteristics obtained from a reference sample, it can be determined that the compositions disclosed herein do not affect the severity or incidence of a disease, disorder, or condition phenotype.In some embodiments, by comparing one or more metabolite levels, parameters, or characteristics obtained from a test sample with one or more metabolite levels, parameters, or characteristics obtained from a reference sample, it can be determined that the compositions disclosed herein prevent a disease, disorder, or condition phenotype.
[0105] The present disclosure also provides the recognition that the compositions and methods provided herein can be used to monitor the progression of a disease, disorder, or condition (e.g., a vagus nerve-related disease, disorder, or condition) in an individual. For example, if a metabolite level, parameter, or feature (e.g., the level of cell survival, the level or activity of nucleic acid or protein, or their form, mitochondrial function, peroxisome function, ATP level, proteasome function, lysosomal function, oxidative stress, inflammation, nerve damage (e.g., due to beta amyloid, tangles, etc.), nerve fiber damage, nerve ending damage, brain damage, etc.) determined to increase the severity of a disease, disorder, or condition decreases in relative amount, it may indicate that the disease, disorder, or condition is attenuated, for example, by a treatment or immune response.
[0106] The present disclosure also provides insight that the compositions and methods provided herein can be used to tailor treatments (e.g., therapeutics, nutraceuticals, and / or probiotics) to individual patients. In some embodiments, the compositions and methods provided herein can provide "personalized" therapy. In some cases, metabolite levels, features, or parameters (e.g., levels of cell survival, levels or activity of nucleic acids or proteins, or their forms, mitochondrial function, peroxisomal function, ATP levels, proteasomal function, lysosomal function, oxidative stress, inflammation, neuronal damage (e.g., due to beta amyloid, tangles, etc.), nerve fiber damage, nerve ending damage, brain damage, etc.) in an individual can be assessed, characterized, or identified to determine whether the individual has a disease, disorder, or condition. Based on the results, the individual can be treated with one or more compositions to adjust metabolite levels (i.e., their metabolome), features, or parameters. In some cases, this will affect the disease, disorder, or condition that the individual suffers from or is at risk of developing. For example, if an individual is determined to have relatively small levels of one or more metabolites determined to reduce the severity of a disease, disorder, or condition, administration to the individual of one or more compositions (or extracts, components, or compounds thereof) determined to reduce the severity of the disease, disorder, or condition may attenuate the severity of the disease or condition in the individual.
[0107] The present disclosure provides insight that the compositions and methods provided herein may be used recursively to treat, prevent, or ameliorate a disease, disorder, or condition. In some embodiments, for example, one or more compositions disclosed herein may be administered (e.g., fed, injected, etc.) to a subject after determining the effect of one or more compositions on the subject's metabolite levels, or after determining the effect of one or more compositions on the subject's characteristics or parameters (e.g., levels of cell survival, levels or activity of nucleic acids or proteins, or their morphology, mitochondrial function, peroxisomal function, ATP levels, proteasomal function, lysosomal function, oxidative stress, inflammation, neuronal damage (e.g., due to beta amyloid, tangles, etc.), nerve fiber damage, nerve ending damage, brain damage, etc.). In some embodiments, the composition may be administered once. In some embodiments, the composition may be administered more than once. In some embodiments, the composition may be administered daily, weekly, biweekly, monthly, bimonthly, etc. In each of these cases, changes in the levels of one or more metabolites, or characteristics or parameters, may be monitored. In some embodiments, changes in the levels or characteristics or parameters of one or more metabolites (e.g., the metabolome) may be monitored prior to administration of the composition. In some embodiments, changes in the levels or characteristics or parameters of one or more metabolites (e.g., the metabolome) may be monitored after administration of the composition.
[0108] Pharmaceutical Compositions Compositions are provided herein that include individual microbial strains, or combinations of microbial strains, their metabolites, their extracts, or their components. In some embodiments, the compositions include individual microbial strains or combinations of microbial strains from mammalian microbiota, their metabolites, their extracts, and / or their components that have been assessed, identified, characterized, or assayed using the methods described herein. In some embodiments, the compositions provided herein include one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more microbial strains from mammalian microbiota, their extracts, their metabolites, and / or their components that have been assessed, identified, characterized, or assayed using the methods described herein.
[0109] Compositions comprising one or more components or metabolites are also provided herein.In some embodiments, the components or metabolites in the compositions herein are derived from a source that is not a microbial strain, for example, are synthetically produced.In some embodiments, the components or metabolites in the compositions may be identified from a microbial strain, but are independent of the microbial strain and are not produced by the microbial strain, for example, they can be synthetically produced.
[0110] In some embodiments, the compositions provided herein comprise two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more microbial strains listed in Table 1 below. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5]
Table 2-6
Table 2-7
Table 2-8
Table 2-9
Table 2-10
Table 2-11
[0111] In some embodiments, the compositions provided herein comprise Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or a combination thereof. In some embodiments, the compositions comprise at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or all of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, and Acidaminococcus sp. In some embodiments, for example, the composition includes all of Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, and Acidaminococcus sp., and may be referred to by different names, including, but not limited to, CT10 composition, CT10 cocktail, etc.
[0112] In some embodiments, the compositions provided herein include Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella sp., Bifidobacterium sp., or combinations thereof. In some embodiments, the compositions include at least two, at least three, at least four, at least five, or all of Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella sp., and Bifidobacterium sp. In some embodiments, for example, the compositions include all of Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella sp., and Bifidobacterium sp., and may be referred to by different names, including, but not limited to, CT6 composition, CT6 cocktail, and the like. In some embodiments, the compositions provided herein include Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus catus, Lactobacillus plantarum, Veillonella atypica, Bifidobacterium breve, or a combination thereof. In some embodiments, the compositions include at least two, at least three, at least four, at least five, or all of Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus catus, Lactobacillus plantarum, Veillonella atypica, and Bifidobacterium breve.In some embodiments, for example, the composition includes all of Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus catus, Lactobacillus plantarum, Veillonella atypica, and Bifidobacterium breve, and may be referred to by different names, including, but not limited to, CT6 composition, CT6 cocktail, etc.
[0113] In some embodiments, the compositions provided herein comprise one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more metabolites. Metabolites that may be assessed, identified, characterized, or assayed for and / or included in the compositions disclosed herein include, for example, those listed in the appendices filed herewith (e.g., Appendix 1-1, 1-2, 1-3, 2, 3, or 4).
[0114] In some embodiments, the metabolite can be butyrylcamitine, theobromine, p-hydroxyphenylpyruvic acid, propionic acid, picolinic acid, 2-hydroxy-4 methylvaleric acid, N6-acetylcysine, urocanic acid, N5-ethylglutamine, trigonelline, stachydrine, ectoine, 5-hydroxylysine, arginine (Arg), cholic acid, 2-(4-hydroxyphenyl)propionic acid, N-acetyltryptophan, hydroxyproline, argininosuccinic acid, glutamic acid (Glu), sarcosine, 5-methoxyindoleacetic acid, indole-3-lactic acid, isovalerylalanine, N-acetylleucine, 1-methylhistidine, N-acetylphenylalanine, proline (Pro), or any combination thereof.
[0115] In some embodiments, the metabolite is 4-hydroxyphenylpyruvate, ectoine, gramine, N-acetyl-L-phenylalanine, nepsilon-acetyl-L-lysine, stachydrine, trigonelline, 3-ureidopropionic acid, theobromine, hippuric acid, imidazolepropionic acid, NG-methyl-L-arginine, transurocanic acid, N-acetyl-L-leucine, sarcosine, isobutyrylcarnitine, b-hydroxyisovaleric acid, L-theanine / N5-ethylglutamine, 5-hydroxylysine, phenaceturic acid, betaine, hydroxyproline, picolinic acid, 2-aminoadipic acid, glycerophosphocholine, carnitine, glycerol 3-phosphate, argininosuccinic acid, creatine, terephthalic acid, homocitrulline, mucic acid, homocysteine sulfinic acid, trimethyllysine, spermidine, glyoxylic acid, XA0013 C6H6O4S, 3-indoxyl sulfate, nicotinamide, N-formylglycine, ureidoglycolate, N-methylproline, glucaric acid, butyrylcarnitine, methionine sulfoxide, carboxymethyllysine, glycolic acid, phenaceturic acid, diethanolamine, phosphorylcholine, guanidinosuccinic acid, N-acetylhistidine, glyceric acid, S-methylmethionine, cysteine glutathione disulfide, kynurenine, N-acetylphenylalanine, threonic acid, malic acid, 7,8-dihydrobiopterin, homovanillic acid, taurocholic acid, 5-methoxyindoleacetic acid, butyrate, b-hydroxyisovaleric acid, 2-oxoglutaric acid, N-acetyltryptophan, thiaproline, hypotaurine, cholic acid, acetoacetic acid, ethanolamine, guanidoacetic acid, S-sulfocysteine, myristic acid C14:0 XA0027, or any combination thereof.
[0116] In some embodiments, the individual microbial strains or combinations of microbial strains are derived from the microbiota of a killed (e.g., heat-killed) mammal. Alternatively, in some embodiments, the individual microbial strains or combinations of microbial strains derived from the microbiota of a mammal may be viable or contain living cells.
[0117] In some embodiments, the one or more microbial strains include viable or living individual microbial strains or combinations of microbial strains, for example, from a mammalian microbiota.
[0118] In some embodiments, the one or more microbial strains include, for example, viable or living individual microbial strains or combinations of microbial strains derived from a mammalian microbiota, and include, and / or are formulated through the use of, one or more cell cultures and / or supernatants or pellets thereof, and / or powders formed therefrom, as described herein.
[0119] In some embodiments, the compositions for use according to the present disclosure are, for example, pharmaceutical compositions for administration (e.g., topical, oral, subcutaneous, intravenous, intramuscular, intracerebral, intrathecal, rectal (e.g., rectal intubation), intraocular, intravitreal, or suprachoroidal administration) to a mammal (e.g., a human). Pharmaceutical compositions typically include an active agent (e.g., an individual or combination of microbial strains from a mammalian microbiota, an extract thereof, and / or a component thereof) and a pharmaceutically acceptable carrier. Certain exemplary pharmaceutically acceptable carriers include, for example, saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration.
[0120] In some embodiments, pharmaceutical compositions for use according to the present disclosure may include and / or be administered in conjunction with one or more supplementary active compounds, and in certain embodiments, such supplementary active agents may be ginger, curcumin, probiotics (e.g., probiotic strains of one or more of the following genera: Lactobacillus, Bifidobacterium, Saccharomyces, Enterococcus, Streptococcus, Pediococcus, Leuconostoc, Bacillus, and / or Escherichia coli (Fijan, Int J Environ Res Public Health. 2014, incorporated herein by reference in its entirety). May;11(5):4745-4767), prebiotics (non-digestible food ingredients that help support the growth of probiotic bacteria, e.g., fructans such as fructooligosaccharides (FOS) and inulin, galactans such as galactooligosaccharides (GOS), dietary fibers such as resistant starch, pectin, beta-glucans, and xylooligosaccharides) (see Hutkins et al., CurrOpinBiotechnol. 2016 Feb;37:1-7, incorporated herein by reference in its entirety), and combinations thereof.
[0121] In some embodiments, the prebiotics include fructooligosaccharides, inulin, isomaltooligosaccharides, lactylol, lactosucrose, lactulose, soybean oligosaccharides, transgalactooligosaccharides, xylooligosaccharides, seaweed, or combinations thereof. In some embodiments, the prebiotics include seaweed. In some embodiments, the prebiotics include pome fruit extract, berry extract, and walnut extract.
[0122] In some embodiments, the probiotic composition may be formulated for oral administration. In some embodiments, the probiotic composition may be a food, beverage, feed composition, or dietary supplement. In some embodiments, the ellagitanin composition, the enzyme composition, or both, may be a liquid, syrup, tablet, lozenge, gummy, capsule, powder, gel, or film. In some embodiments, the probiotic composition is an enteric coated formulation.
[0123] In some embodiments, the probiotic comprises a prebiotic, which in some embodiments comprises fructooligosaccharides, inulin, isomaltooligosaccharides, lactylol, lactosucrose, lactulose, soybean oligosaccharides, transgalactooligosaccharides, xylooligosaccharides, seaweed, pome fruit extract, berry extract, and walnut extract, or a combination thereof.
[0124] A pharmaceutical composition is typically formulated to be compatible with its intended route of administration. Examples of routes of administration include topical, oral, subcutaneous, intravenous, intramuscular, intracerebral, intrathecal, rectal (e.g., rectal intubation), intraocular, intravitreal, or suprachoroidal administration. Methods for formulating suitable pharmaceutical compositions are known in the art, see, for example, Remington: The Science and Practice of Pharmacy, 21st ed., 2005, and the books in the series Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs (Dekker, NY), which are incorporated herein by reference in their entirety. Oral compositions generally include an inert diluent or an edible carrier (e.g., a pharma- ceutically acceptable diluent, a pharma- ceutically acceptable carrier). In some embodiments, oral formulations can be or include syrups, liquids, tablets, lozenges, gummies, capsules, such as gelatin capsules, powders, gels, films, and the like, to name just a few. Similarly, ophthalmic compositions (e.g., for intraocular, intravitreal, or suprachoroidal administration) may include various additives, such as inert diluents or carriers (e.g., pharma- ceutically acceptable diluents, pharma-ceutically acceptable carriers), viscosity enhancers, permeation enhancers, cyclodextrins, and the like. Examples of viscosity enhancers include hydroxymethylcellulose, hydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, and polyhydric alcohols. Examples of permeation enhancers include chelating agents, preservatives, surfactants, bile salts, benzalkonium chloride, polyoxyethylene glycol ethers (lauryl, stearyl, and oleyl), ethylenediaminetetraacetic acid sodium salt, sodium taurocholate, saponin, and Cremophor EL, and the like. For example, in some embodiments, the ophthalmic formulation may be or include a suspension, an emulsion (e.g., water-in-oil or oil-in-water), a nanocarrier, (e.g., nanoparticles, nanosuspensions, liposomes, nanomicelles, dendrimers, and the like), an ointment, a gel, an eye drop, and the like.The brain composition (e.g., for intracerebral or intrathecal administration) may include an inert diluent or carrier, and / or an additive. In some embodiments, the brain composition does not include a preservative. In some embodiments, the brain composition is sterile.
[0125] In some embodiments, pharma- ceutical compatible binders and / or adjuvant materials can be included as part of the pharmaceutical composition. In some particular embodiments, the pharmaceutical composition can contain, for example, any one or more of the following inactive ingredients or compounds of a similar nature: binders such as microcrystalline cellulose, gum tragacanth, or gelatin; excipients such as starch or lactose; disintegrants such as alginic acid, Primogel, or corn starch; lubricants such as magnesium stearate or sterotes; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavorings such as peppermint, methyl salicylate, or orange flavoring. In some embodiments, the composition can be taken as is, or sprinkled on or mixed into food or liquid (such as water). In some embodiments, compositions that can be administered to a mammal described herein can be or can include ingestible items (e.g., foods or beverages) that contain (e.g., are supplemented with) individual or combinations of microbial strains from the mammal's microbiota, extracts thereof, and / or components thereof.
[0126] In some embodiments, the food product can be or include one or more of bars, candies, baked goods, cereals, savory snacks, pasta, chocolate, and other solid foods, liquid or semi-solid foods, including yogurt, soups, and stews, and beverages, such as smoothies, shakes, juices, and other carbonated or non-carbonated beverages. In some embodiments, the food product is prepared by the subject by mixing individual or combinations of microbial strains from a mammal's microbiota, extracts thereof, and / or components thereof.
[0127] The compositions can be included in a kit, container, pack, or dispenser together with instructions for administration or use in the methods described herein.
[0128] Those of skill in the art will understand upon reading this disclosure that in some embodiments, the compositions (e.g., pharmaceutical compositions) described herein can be or include one or more cells, tissues, or organisms (e.g., plant or microbial cells, tissues, or organisms) that produce (e.g., have produced and / or are producing) the relevant compound.
[0129] Those skilled in the art will appreciate that in some embodiments, techniques for preparing and / or preparing compositions and / or preparations (particularly for preparing pharmaceutical compositions) may include one or more steps of evaluating or characterizing the compound, preparation, or composition, e.g., as part of quality control. In some embodiments, if an assayed material does not meet predetermined specifications for relevant evaluation, it is discarded. In some embodiments, if such assayed material meets predetermined specifications, it continues to be processed as described herein.
[0130] In some embodiments, the pharmaceutical compositions provided herein can promote colonization of individual microbial strains or combinations of microbial strains from a mammalian microbiota, particularly microbial strain(s) that have been identified, characterized, or evaluated as decreasing the severity or incidence of a mammalian disease, disorder, or condition in a mammal suffering from or at risk for the mammalian disease, disorder, or condition. In some embodiments, the pharmaceutical compositions provided herein can attenuate colonization of individual microbial strains or combinations of microbial strains from a mammalian microbiota, particularly microbial strain(s) that have been identified, characterized, or evaluated as increasing the severity or incidence of a mammalian disease, disorder, or condition (e.g., a vagus nerve-related disease, disorder, or condition) in a mammal suffering from or at risk for the mammalian disease, disorder, or condition. In some embodiments, the pharmaceutical compositions provided herein are capable of promoting colonization of individual microbial strains or combinations of microbial strains from the microbiota of a mammal, particularly a microbial strain(s) that have been identified, characterized, or evaluated as not affecting the severity or incidence of a mammalian disease, disorder, or condition, but that have been identified, characterized, or evaluated as being capable of outcompeting one or more microbial strains that have been identified, characterized, or evaluated as increasing the severity or incidence of a mammalian disease, disorder, or condition, in a mammal suffering from or at risk for the mammalian disease, disorder, or condition.
[0131] In some embodiments, each of the one or more microbial strains in the composition is at least 10 1 Colony forming units (CFU) ~10 20 In some embodiments, each of the one or more microbial strains in the composition comprises 10 1 Colony forming units (CFU) ~10 15 In some embodiments, each of the one or more microbial strains in the composition comprises 10 6 CFU~10 15In some embodiments, each of the one or more microbial strains in the composition comprises about 10 1 CFU~10 15 CFU, or about 10 2 CFU~10 14 CFU, or about 10 3 CFU~10 13 CFU, or about 10 4 CFU~10 13 CFU, or about 10 5 CFU~10 12 CFU, or about 10 6 CFU~10 11 CFU, or about 10 7 CFU~10 10 CFU, or about 10 8 CFU~10 9 CFU, or about 10 5 CFU~10 10 CFU, or about 10 8 CFU~10 12 In some embodiments, each of the one or more microbial strains in the composition comprises at least about 10 1 , 5×10 1 , 10 2 , 5×10 2 , 10 3 , 5×10 3 , 10 4 , 5×10 4 , 10 5 , 5×10 5 , 10 6 , 5×10 6 , 10 7 , 5×10 7 , 10 8 , 5×10 8 , 10 9 , 5×10 9 , 10 10 , 5×10 10 , 10 11 , 5×10 11 , 10 12 In some embodiments, each of the one or more microbial strains in the composition comprises at most about 10 15 , 5×10 14 , 10 14 , 5×10 13, 10 13 , 5×10 12 , 10 12 , 5×10 11 , 10 11 , 5×10 10 , 10 10 , 5×10 9 , 10 9 , 5×10 8 , 10 8 In some embodiments, each of the one or more microbial strains in the composition comprises the same number of CFUs. In some embodiments, some of the one or more microbial strains in the composition comprise different numbers of CFUs.
[0132] In some embodiments, the composition comprises a total of 10 1 CFU~10 20 In some embodiments, the composition comprises a total of 10 6 CFU~10 15 In some embodiments, the composition comprises about 10 1 CFU~10 20 CFU, or about 10 5 CFU~10 15 CFU, or about 10 5 CFU~10 12 CFU, approximately 10 5 CFU~10 10 CFU, or about 10 8 CFU~10 12 In some embodiments, the composition may comprise about 10 CFU of one or more microbial strains. 1 CFU~10 15 CFU, or about 10 2 CFU~10 14 CFU, or about 10 3 CFU~10 13 CFU, or about 10 4 CFU~10 13 CFU, or about 10 5 CFU~10 12 CFU, or about 10 6 CFU~10 11 CFU, or about 10 7 CFU~10 10CFU, or about 10 8 CFU~10 9 CFU, or about 10 5 CFU~10 10 CFU, or about 10 8 CFU~10 12 In some embodiments, the composition may comprise at least about 10 CFU of one or more microbial strains. 1 , 5×10 1 , 10 2 , 5×10 2 , 10 3 , 5×10 3 , 10 4 , 5×10 4 , 10 5 , 5×10 5 , 10 6 , 5×10 6 , 10 7 , 5×10 7 , 10 8 , 5×10 8 , 10 9 , 5×10 9 , 10 10 , 5×10 10 , 10 11 , 5×10 11 , 10 12 In some embodiments, the composition may contain at most about 10 CFU of one or more microbial strains. 15 , 5×10 14 , 10 14 , 5×10 13 , 10 13 , 5×10 12 , 10 12 , 5×10 11 , 10 11 , 5×10 10 , 10 10 , 5×10 9 , 10 9 , 5×10 8 , 10 8 The culture may contain one or more microbial strains at or below CFU.
[0133] In some embodiments, a pharmaceutical composition is tailored to a particular mammal (e.g., a particular human, e.g., a patient) based on the microbiota of that mammal (e.g., a human). In some embodiments, a pharmaceutical composition is specific to the microbiota of an individual mammal (e.g., a human). In some embodiments, a pharmaceutical composition is specific to the microbiota of a population of mammals (e.g., humans). A population of mammals can include, but is not limited to, a family, mammals in the same geographic location (e.g., neighborhood, city, state, or country), mammals having the same disease or condition, mammals of a particular age or age range, mammals consuming a particular diet (e.g., foods, food sources, or caloric intake).
[0134] Treatment methods The present disclosure recognizes that the compositions described herein may be useful for treating a subject. The methods provided by the present disclosure include methods for the treatment of certain diseases, disorders, and conditions. In some embodiments, the relevant diseases, disorders, and conditions may be or include vagus nerve-related diseases, disorders, or conditions. In some embodiments, the vagus nerve-related diseases, disorders, or conditions may be AD, PD, ALS, autism spectrum disorder, rheumatoid arthritis, hypertension, heart failure, diabetes, arrhythmia, IBD, fatty liver disease, depression, epilepsy, bipolar disorder, anxiety, PTSD, MS, autoimmune diseases, obesity, AP, eye diseases including retinal ischemia / reperfusion (I / R) injury, COPD, mood disorders, migraine and cluster headaches, eating disorders, anorexia, psoriasis and psoriatic arthropathy, endocrine tumors and vagus nerve paragangliomas, heartburn, GERD, SIBO, IBS, celiac disease, chronic constipation, kidney disease, endometriosis, aging, infertility including vascular disease.
[0135] Generally, the methods of treatment provided by the present disclosure involve administering to a subject in need of, or determined to be in need of, such treatment a therapeutically effective amount of a composition described herein, alone or in combination with other compositions and / or treatments.
[0136] In some embodiments, the methods of treatment provided herein are prophylactic or preventative, e.g., may be administered to a subject prior to the display of noticeable symptoms and / or prior to exposure to a particular anticipated inducer associated with a vagus nerve-related disease, disorder, or condition described herein. In some embodiments, the methods of treatment provided herein are therapeutic, e.g., may be administered to a subject following the onset of noticeable symptoms associated with a vagus nerve-related disease, disorder, or condition.
[0137] In some embodiments, the methods of treatment provided are administered to a subject that is a mammal, e.g., a mammal experiencing a disease, disorder, or condition described herein, and in some embodiments the subject is a human or non-human animal subject, e.g., an ape, a cat, a monkey, or a pig.
[0138] In many embodiments, the treatment involves ameliorating at least one symptom of a disease, disorder, or condition associated with a vagus nerve-related disease, disorder, or condition. In some embodiments, the method of treatment can be prophylactic.
[0139] In some embodiments, the methods may involve administration of a therapeutically effective amount of a composition disclosed herein before, during (e.g., simultaneously with), or after administration of a treatment expected to be associated with a vagus nerve-related disease, disorder, or condition.
[0140] In some embodiments, a subject receiving a treatment described herein may be undergoing and / or may have been undergoing other therapies (e.g., pharmacological treatments / therapies, surgery, etc.) that may be intended to treat, for example, one or more symptoms of a disease, disorder, or condition described herein (e.g., a vagus nerve-related disease, disorder, or condition), and thus the provided compositions are administered in combination with such other therapies (i.e., treatments) to treat the relevant disease, disorder, or condition.
[0141] In some embodiments, the compositions described herein may be administered in a form containing one or more pharma- ceutically acceptable carriers. Suitable carriers have been described previously and vary with the desired form and mode of administration of the composition. For example, pharma- ceutically acceptable carriers may include diluents or excipients, such as fillers, binders, wetting agents, disintegrants, surfactants, glidants, and lubricants. Typically, carriers may be solids (including powders), liquids, or any combination thereof. Each carrier is preferably "acceptable" in the sense that it is compatible with the other ingredients in the composition and not harmful to the subject. Carriers may be biologically acceptable and inert (e.g., allowing the composition to maintain the viability of biological materials until delivered to the appropriate site).
[0142] Tablets, pills, capsules, troches, and the like can contain any of the following ingredients, or compounds of a similar nature: binders such as microcrystalline cellulose, gum tragacanth, or gelatin, excipients such as starch or lactose, disintegrants such as alginic acid, primogel, or corn starch, lubricants such as magnesium stearate or sterotes, glidants such as colloidal silicon dioxide, sweeteners such as sucrose or saccharin, or flavorings such as peppermint, methyl salicylate, orange flavoring, or other suitable flavors. These are for purposes of example only and are not intended to be limiting.
[0143] Oral compositions can include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with an excipient and used in the form of tablets, lozenges, drops, troches, or capsules, such as gelatin capsules. Oral compositions can also be prepared by combining the compositions of the present disclosure with food. In some embodiments, the microorganism (e.g., one or more microbial strains) can be formulated into food. Some non-limiting examples of food that can be used with the methods and compositions described herein include popsicles, cheese, cream, chocolate, milk, meat, beverages, pickled vegetables, kefir, miso, sauerkraut, and the like. In other embodiments, the food may be juice, soft drinks, tea drinks, beverage preparations, jelly drinks, and functional drinks, alcoholic beverages such as beer, carbohydrate-containing foods such as rice foods, noodles, bread, and pasta, paste products such as fish, ham, sausage, seafood paste products, curry, foods with thick starchy sauces, and retort pouch products such as Chinese soup, dairy products such as soup, milk, milk drinks, ice cream, and yogurt, fermented products such as fermented soybean paste, fermented beverages, and pickles, soy products, various confectionery products including biscuits, cookies, and the like, candy, chewing gum, gummies, jellies, cream caramel, and cold desserts including frozen desserts, instant foods such as instant soups and instant miso soup, and the like. It is preferred that the food preparation does not require cooking after mixing with the microbial strain(s) to avoid killing any microorganisms. In one embodiment, the food used for administration is chilled, for example iced, flavored water. In certain embodiments, the food product is not a potentially allergenic food (e.g., not soy, wheat, peanut, tree nut, dairy, egg, shellfish, or fish). Pharmaceutically compatible binding agents, and / or adjuvant materials can be included as part of the composition.
[0144] Ophthalmic formulations (e.g., for intraocular, intravitreal, or suprachoroidal administration) can include inert diluents or carriers. For the purpose of ophthalmic therapeutic administration, active compounds can be incorporated with excipients and used in the form of suspensions, emulsions (e.g., water-in-oil or oil-in-water), nanocarriers, (e.g., nanoparticles, nanosuspensions, liposomes, nanocells, dendrimers, etc.), ointments, gels, eye drops, etc. In some embodiments, administration of such formulations is topical (e.g., eye drops). In some embodiments, administration of such formulations is via injection (e.g., intravitreal, suprachoroidal, etc.).
[0145] Brain preparations (e.g., for intracerebral or intrathecal administration) can include inert diluents or carriers. For the purpose of brain therapeutic administration, active compounds can be incorporated with excipients and used in the form of suspensions, emulsions (e.g., water-in-oil or oil-in-water), nanocarriers, (e.g., nanoparticles, nanosuspensions, liposomes, nanocells, dendrimers, etc.), ointments, gels, etc. In some embodiments, administration of such formulations is local (e.g., ointments). In some embodiments, administration of such formulations is via injection (e.g., intracerebral, intrathecal, etc.).
[0146] In some such embodiments, the compositions described herein are administered to a subject according to a dosing schedule that achieves the administration of cells into the microbiota of the subject.In some embodiments, the compositions are administered to a subject in a single dose.In some embodiments, the compositions are administered to a subject in multiple doses.In some embodiments, a single dose of the composition is administered to a subject twice a day, daily, weekly, or monthly.
[0147] In some embodiments, each of the one or more microbial strains in a dose is 10 1 ~10 15 In some embodiments, each of the one or more microbial strains in a dose comprises 10 6 ~10 15In some embodiments, each of the one or more microbial strains in a dose contains the same number of CFU. In some embodiments, some of the one or more microbial strains in a dose contain different numbers of CFU.
[0148] In some embodiments, a single dose of one or more microbial strains comprises a total of 10 6 ~10 15 In some embodiments, a single dose of one or more microbial strains comprises a total of 10 7 ~10 15 In some embodiments, a single dose of the one or more microbial strains comprises between 5 and 200 billion CFU. In some embodiments, a single dose of the one or more microbial strains comprises between 5 and 50 billion CFU. In some embodiments, a single dose of the one or more microbial strains comprises between 5 and 20 billion CFU. In some embodiments, a single dose of the one or more microbial strains comprises between 5 and 100 billion CFU. In some embodiments, a single dose of the one or more microbial strains comprises between 100 and 200 billion CFU.
[0149] In some embodiments, efficacy can be evaluated by measuring the degree of cellular oxidative stress in biological samples before and after administration of the compositions described herein.The degree of cellular oxidative stress can be evaluated, for example, by measuring the expression of oxidative stress biomarkers, such as reactive oxygen species (ROS) levels, or lipid, protein, and nucleic acid damage levels, or by determining the ratio of oxidized to reduced forms of one or more biomarkers.Since high levels of oxidative stress can be cytotoxic, the degree of oxidative stress can be measured by evaluating the concentration of intracellular proteins present in the systemic circulation from inflamed or lysed cells (e.g., neuronal cells). EXAMPLES
[0150] Example Thorough details of the objectives, mouse models used, studies performed, and results of these examples are listed in Appendix 5 submitted herewith.
[0151] Example 1: In vivo evaluation of the effects of metabolites on LPS-induced cytokine production in human monocytes This example provides an in vivo assessment of the effects of specific metabolites on cytokine production in human monocytes.
[0152] STUDY: THP-1 monocytic cell line was purchased from ATCC and cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 0.05 mM 2-mercaptoethanol. Cells were maintained at 37°C in 5% CO2 in an incubator. All experiments were performed using only passage 3-7 cells. For 6-well plates, cells were cultured at 1 × 10 using a total volume of 3 mL (300,000 cells total). 5 Cells were seeded at a density of 10 ...
[0153] Results: Figures 2A-C show the cytokine levels of each of the various metabolites tested and controls for eight (8) different cytokines. The changes in cytokine levels using metabolites in monocytes suggest that one or more of these metabolites can be used to modulate, reduce, or reverse inflammation (e.g., including neuroinflammation), which in turn can be used to treat and / or prevent vagus nerve-related disorders as described herein.
[0154] References Bonaz, B., et al., Anti-inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation.J Physiol 594.20(2016)pp 5781-5790.
[0155] Martin, CR, et al., The Brain-Gut-Microbiome Axis.Cell Mol Gastroenterol Hepatol(2018)6:pp 133-148.
[0156] Berthoud, HR, and Neuhuber, WL, Functional and chemical anatomy of the afferent vagal system, Autonomic Neuroscience: Basic and Clinical 85(2000) 1-17.
[0157] Fulling, C., et al., Gut Microbe to Brain Signaling: What Happens in Vagus, Neuron 101, 2019.
[0158] Bonaz,B.,et al.,Vagal tone:effects on sensitivity,motility,and inflammation,Neurogastroenterol Motil(2016)28,455-462.
[0159] Breit,S.,et al.,Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorders,Frontiers in Psychiatry,2018,9,44.
[0160] Browning,K.N.,et al.,The Vagus Nerve in Appetite Regulation,Mood,and Intestinal Inflammation,Gastroenterology,2017,152,pp 730-744.
[0161] Bonaz,B.,et al.,The Vagus Nerve in the Neuro-Immune Axis:Implications in the Pathology of the Gastrointestinal Tract,Frontiers in Immunology,2017,8,1452.
[0162] Bonaz,B.,et al.,The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis,Frontiers in Neuroscience,2018,12,49.
[0163] Lkhagvasuren,B.,et al.,Pancreas-Brain Crosstalk,Frontiers in Neuroanatomy,2021,15,691777.
[0164] Rosas-Ballina, M., et al., Acetylcholine-Synthesizing T Cells Relay Neural Signals in a Vagus Nerve Circuit,Science.2011 October 7;334(6052):98-101.doi:10.1126 / science.1209985.
[0165] Carnevale, D., et al., A cholinergic-sympathetic pathway primes immunity in hypertension and mediates brain-to-spleen communication, Nature Communications, 2016, 7, 13035.
[0166] Nakamura, Y., and Inoue, T., Neuroimmune Communication in the Kidney, JMA Journal, 2020, Volume 3, Issue 3.
[0167] Other embodiments It will be understood by those skilled in the art that various changes, modifications, and improvements to the present disclosure will be readily suggested to those skilled in the art. Such changes, modifications, and improvements are intended to be part of this disclosure and are intended to be within the spirit and scope of the present invention. Therefore, the foregoing description and drawings are by way of example only, and any inventions described in this disclosure, as further described in detail by the following claims, are within the spirit and scope of the present invention.
[0168] Those of ordinary skill in the art will understand the typical standard deviation or error attributable to values obtained from assays or other processes described herein. Publications, websites, and other reference materials referenced herein to describe the background of the invention and to provide additional details regarding its practice, including those listed in the References section above, are hereby incorporated by reference in their entireties.
[0169] While embodiments of the invention have been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate, but not to limit, the scope of the invention as defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
[0170] Equivalent Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the invention is not intended to be limited to the above Description, but rather is as set forth in the following claims. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] Appendix 1-3 Metabolites of interest C10H10O3S C32H30O12 C6H10O8 1-Methyl-4-imidazole acetic acid 1-Methyladenosine 1-Methylhistamine 1-Methylhistidine 3-Methylhistidine 1-Methylhistidine; 3-Methylhistidine 1-Methylnicotinamide 1-Palmitoyl-glycero-3-phosphocholine-1 1,2-Dipalmitoyl-glycero-3-phosphoethanolamine-1 1,2-Dipalmitoyl-glycero-3-phosphoethanolamine-2 11-amino-undecanoic acid 15(S)-HETE 17α-hydroxyprogesterone 17α-hydroxyprogesterone-2 Deoxycorticosterone-2 1H-imidazole-4-propionic acid 1H-Imidazole-4-propionic acid; 1-Methyl-4-imidazoleacetic acid 2-(beta-D-glucosyl)-sn-glycerol 2-Aminoadipic Acid 2-Aminoisobutyric acid 2-Aminobutyric acid 2-Arachidonoylglycerol 2-Diethylaminoethanol 2-Hydroxy-4-methylvaleric acid 2-Hydroxybutyric Acid 2-Hydroxyglutaric acid 2-Hydroxyisobutyric Acid 2-Hydroxyvaleric acid 2-Keto-glutaric acid 2-Methylserine 2-Oxoarginine 2-Oxoglutaric Acid 2-Oxoisovaleric acid 2-oxoisovaleric acid; 2-oxoisovaleric acid 2-Phosphoglyceric acid 2-Phosphoglyceric acid; 3-Phosphoglyceric acid 2-Thiopheneacetic acid 2,3-Diphosphoglyceric Acid 2,6-Diaminopimelic Acid 2'-Deoxycytidine 2'-Deoxyuridine 20α-hydroxyprogesterone 21-Deoxycortisol-2 21-Hydroxypregnenolone 3-(4-hydroxyphenyl)propionic acid 2-(4-hydroxyphenyl)propionic acid 3-(3-hydroxyphenyl)propionic acid 3-(4-hydroxyphenyl)propionic acid;2-(4-hydroxyphenyl)propionic acid;3-(3-hydroxyphenyl)propionic acid;Tropic acid;3-(2-hydroxyphenyl)propionic acid;m-Ethoxybenzoic acid;3-phenyllactic acid;p-Methoxyphenylacetic acid 3-cis-hydroxy-b,e-caroten-3'-one 3-Guanidinopropanoate 3-Hydroxy-2-methyl-4-pyrone 3-Hydroxy-3-methylglutaric acid 3-Hydroxy-3',4'-didehydro-β,γ-carotene 3-Hydroxybutyric Acid 3-Hydroxybutyric acid; 2-Hydroxybutyric acid; 2-Hydroxyisobutyric acid 3-Hydroxybutyric acid; 2-Hydroxyisobutyric acid 3-Hydroxyglutaric acid 3-Hydroxytetradecanoic acid-1 3-Indoxyl Sulfate 3-Mercaptolactic Acid 3-Methylhistamine; 1-Methylhistamine 3-Methylhistidine; 1-Methylhistidine 3-Oxocholic Acid 3-Phosphoglyceric acid 3-Ureidopropionic acid 3,4-Dihydroxyhydrocinnamic acid;Homovanillic acid;Hydroxyphenyllactic acid 4-Acetamidobutanoic acid 4-Guanidinobutyric Acid 4-Hydroxyquinoline 4-Methyl-2-oxovaleric acid 3-Methyl-2-oxovaleric acid 2-Oxohexanoic acid 4-Methyl-2-oxovaleric acid;3-Methyl-2-oxovaleric acid;2-Oxohexanoic acid 4-Oxypyrrolidine-2-carboxylic acid 5-Amino-4-hydroxynaphthalene-1,3-disulfonic acid 5-Amino-4-oxovaleric acid 5-Hydroxyindoleacetic acid 5-Hydroxylysine 5-Hydroxypentanoic acid;fA-Hydroxyisovaleric acid;2-Hydroxyvaleric acid 5-Hydroxytryptophan 5-Isopropyl-2'-deoxyuridine triphosphate 5-Methoxyindoleacetic acid; Indole-3-lactic acid 5-Methyl-2'-deoxycytidine 5-Oxoproline 5α-Cholestan-3-one-1 5α-Cholestan-3-one-2 5α-Pregnan-3,20-dione 6-Hydroxyhexanoic acid 6-Hydroxyhexanoic acid; 2-Hydroxy-4-methylvaleric acid 6-Hydroxynicotinic Acid 7-Dehydrocholesterol 7-Dehydrocholesterol 7-Dehydrocholesterol-2 Desmosterol-2 7-Dehydrocholesterol-3 Desmosterol-3 7-Methoxy-2-methylisoflavone 7-Methylguanine 7-Methylguanine; 3-Methylguanine 7,8-Dihydrobiopterin 7,8-Dihydroneopterin Abietic acid Abietic acid-1 Abietic acid-3 AC(10:0) AC(12:0)-1 AC(12:0)-2 AC(12:1) AC(12:1)-1 AC(12:1)-3 AC(13:1) AC(13:1)-1 AC(14:0)-1 AC(14:0)-2 AC(14:1)-1 AC(14:1)-2 AC(14:1)-3 AC(14:1)-4 AC(14:2)-1 AC(14:2)-2 AC(14:2)-3 AC(14:3)-1 AC(14:3)-2 AC(14:3)-3 AC(14:3)-4 AC(15:0)-1 AC(15:0)-2 AC(16:1) AC(16:2)-1 AC(16:2)-2 AC(17:0)-1 AC(17:0)-2 AC(17:1) AC(18:0) AC(18:1) AC(18:2)-1 AC(18:2)-2 AC(20:0) AC(20:1) AC(22:0) Acetohydroxamic acid;Gly ADMA;SDMA ADP ADP-ribose AEA(22:6) Ala ala ser / gly thr Aminoacetone AMP AMP; dGMP Anandamide ANDS(C-SCOPE IS) Anserine Arachidic acid Arachidonic acid Arg Argininosuccinic Acid Ascorbic acid Asiatic Acid Asiatic Acid-1 Asn Asp Asp Asp Pro Ser Asp Gly His Asp Asp Leu Asn Arg Asp-Pro ATP Baicalein Behenic acid Betaine Betaine aldehyde + H2O Betulinic Acid Betulinic Acid-2 Biopterin Biotin Butyrylcarnitine C;C C3H8N4O C4H7NO4 C5H12N2O2 C5H6O7 C6H10O8 C6H11NO2 C6H12N2O3 C7H9N3O2 C8H17NO C8H18N2O3 C9H18N2O cAMP Campesterol Carbachol Carboxymethyl Lysine Carnitine Carnosine Carnosine;His-Ala;Ala-His Chenodeoxycholic acid cholesterol Cholesterol sulfate Cholic acid Colin cis-11-eicosenoic acid Cis-11,14-eicosadienoic acid-1 Cis-11,14-eicosadienoic acid-2 cis-4,7,10,13,16,19-docosahexaenoic acid Cis-5,8,11,14,17-eicosapentaenoic acid EPA Cis-8,11,14-eicosatrienoic acid Cis-Aconitic Acid Citric acid Citrulline Corosolic acid Cortexolone Corticosterone 21-Deoxycortisol-1 Cortisol 18-Hydroxycorticosterone Humulon Creatine Creatinine Crotonic Acid CSA; Cyclodopa glucoside Cyclohexylamine Cys Cys Csy Asn Asn Cystathionine Cysteine Glutathione Disulfide Cystine Cytidine Cytosine Daidzein Dansylic acid (C-SCOPE IS) Deoxycholic Acid Dethiobiotin dGDP;ADP dGTP;ATP Diethanolamine Dimethylaminoethanol DOPA DPA;DPA Dyphylline Ectoine Erucic Acid Ethanolamine Ethanolamine Phosphate Ethyl arachidonate Ethyl Glucuronide FA 16:1 FA C18:1 FA(12:0) FA(13:0) FA(14:1) FA(14:1)-2 FA(14:2)-1 FA(14:2)-2 FA(14:3) FA(15:0) FA(15:0)-1 FA(15:1) FA(15:1)-2 FA(16:2)-1 FA(16:2)-2 FA(16:3 FA(16:3)-2 FA(17:0) FA(17:1) FA(17:2) FA(17:3) FA(19:0) FA(19:0)-1 FA(19:1) FA(19:2) FA(20:3) FA(22:2) FA(22:3)-1 FA(22:3)-2 FA(22:4)-1 FA(22:4)-2 FA(22:5)-1 FA(22:5)-2 FA(24:0) FA(24:2) FA(24:4) FA(24:5)-1 FA(24:5)-2 Flavanones Formiminoglutamic Acid Formononetin Fucosyltryptophan Fucosyl-lysine Fumaric acid fA-Ala fA-Butyrobetaine fA-Glu-Gly fA-Glu-Met fA-Glu-Phe fA-Glu-Ser fA-Glu-Tyr fA-Glu-Val-Gly GABA GABA; 3-aminoisobutyric acid Galactosyl Hydroxylysine Galacturonic acid-1 Glucuronic acid-1 Galacturonic acid; Glucuronic acid Gamma-Glu-Gln GDP Genistein Gln Glu Glu;isoglutamic acid;threo-fA-methylaspartic acid;N-methylaspartic acid;N-acetylserine Glucaric acid Gluconic acid Gluconolactone Glucosamine Glucosamine-6-sulfate Glucose-6-phosphate Glucosyl-glycerol Glutaric acid Methylsuccinic acid Glutaric acid; Methylsuccinic acid Glutathione (GSSG)_Divalent Gly Gly-Lys Gly-Ala Gly-Asp Gly-Asp; Asp-Gly Gly-Leu;N-acetyl-lysine;Val-Ala;Ala-Val;Leu-Gly Glyceric acid Glycerol Glycerol-3-phosphate Glycerophosphocholine Glycitein Glycophenodeoxycholic acid Glycocholic acid Glycodeoxycholic acid Glyoxylic Acid GMP Guanidinosuccinic acid Guanidoacetic acid Gulonolactone; Gluconolactone Hecogenin Henicosylic acid 19-Methylarachidic Acid Heptadecanoic acid-1 FA(17:0)-1 Heptadecanoic acid-2 FA(17:0)-2 Heptanoic acid Hexanoic acid hippuric acid Hippuric acid (benzylglycine) His His Pro Ser Val Arg Tyr Thr His-Asp histamine Homoarginine Homoproline Betaine Homocarnosine Homocitrulline Homocysteine sulfinic acid Homoserine Homovanillic acid Hydroxyphenyl Lactic Acid Hydroxyindoles Hydroxyoctanoic acid Hydroxyprogesterone caproate Hydroxyproline Hydroxytetradecanoic acid Hyodeoxycholic acid Hypotaurine IDP Ile Ile;Leu;Alloisoleucine Ile;Leu;fA-Leucine;Alloisoleucine;6-Aminohexanoic acid Imidazole-4-acetic acid Imidazole Lactate IMP Indole-3-acetic acid Indole-3-carboxaldehyde Indole-3-lactic acid-1 5-Methoxyindoleacetic acid-1 Indole-3-lactic acid; 5-Methoxyindoleacetic acid Indole-3-propionic acid Indole-3-propionic acid (IPA) Inosine 2',3'-cyclic phosphate cIMP Isethionic Acid Isobutyrylcarnitine; Butyrylcarnitine Isocitric Acid Isoglutamic acid Isoliquiritigenin-1 Isoliquiritigenin-2 Isoliquiritigenin-3 Isonicotinamide; Nicotinamide Isovalerylalanine-2 N-acetyl-leucine-2 Isovalerylalanine; N-Acetylleucine Isovalerylcarnitine Kynurenic acid Kynurenine Lactamide Lactic acid Lanosterol Lauric Acid Leu Leukotriene B4 Linoleic acid Linolenic Acid Linoleylethanolamide Liquiritigenin Lithocholic acid Luteolin Lys Lys-Asp Lys-Val Malic acid Mannosamine MCA Met Methionine sulfone Methionine sulfoxide Methylmalonic acid; Succinic acid Morpholine Mucinous acid Myristic acid Myristic Acid 14:0 Myristoleic acid N-(1-deoxy-1-fructosyl)valine N-Acetyl-Beta-Alanine N-Acetyl-β-alanine N-Acetylalanine N-Acetylalanine; N-acetyl-fA-alanine N-Acetylasparagine N-acetylaspartic acid N-Acetylgalactosamine; N-Acetylglucosamine; N-Acetylmannosamine N-Acetylglucosamine N-Acetylglutamic Acid N-Acetylglutamine N-Acetylglycine N-Acetylhistidine N-Acetyl Leucine N-Acetyl Lysine N-Acetylmethionine N-acetylneuraminic acid N-Acetylornithine N-Acetylphenylalanine N-acetyltryptophan N-Acetyl Tyrosine N-Carbamylglutamic Acid N-Carboxymethylserine N-Ethylmaleimide + H2O N-Formyl Aspartic Acid N-Formylglycine N-Formylmethionine N-glycolylneuraminic acid N-Hydroxy-L-tryptophan N-Methylethanolamine phosphate N-Methylproline N,N-Dimethylglycine N'-Formylkynurenine N1-Acetylspermidine N1-Acetylspermidine; N8-Acetylspermidine N1-Methyl-4-pyridone-5-carboxamide N1-Methylguanosine N5-Ethylglutamine N5-Ethylglutamine; N-Acetylornithine N6-Acetyl Lysine N6-Methyl-2'-deoxyadenosine N6-Methyllysine N6,N6,N6-Trimethyllysine Naringenin Nervonic Acid Nerbonylcarnitine Propylbetaine (triethylamine) Nf-Formylkynurenine Nicotinamide No match Norophthalmic Acid Norvaline; 2-Amino-2-methylbutyric acid; 5-Aminovaleric acid; Val Nω-Methylarginine O-Acetylcarnitine O-Acetylhomoserine o-Coumaric acid p-Coumaric acid o-Hydroxybenzoic acid Oleanolic Acid Oleic Acid Oleoylethanolamide AEA(18:1) Ophthalmic Acid Ornithine Orotidine; Uridine; Pseudouridine p-Hydroxyphenylpyruvic acid p-Hydroxyphenylpyruvic acid; Caffeic acid Palmitic acid Palmitoleic acid Palmitoylcarnitine Palmitoylethanolamide Pantothenic acid Penicillamine Penicillamine;Met Pentadecanoic acid Phe Phe Met His Glu Phe Phe Trp Trp Phe-Thr Phenaceturic Acid Phenol Phenyl sulfate Phenylpyruvic Acid Phosphocreatine Phosphoenolpyruvate Phosphorylcholine Picolinic Acid Pipecolic Acid Pipecolic acid;N-methylproline;1-aminocyclopentanecarboxylic acid Piperidine Pro Pro-Gly;Gly-Pro Progesterone Proline Betaine Propionylcarnitine XC0061 Propionylcarnitine;XC0061 Prostaglandin E1-1 Prostaglandin D1-1 Prostaglandin E1-2 Prostaglandin D1-2 Putrescine Pyridoxal Pyrrolidine Pyruvate Retinol Vitamin A Retinol-2 Riboflavin Ribose-5-phosphate Ribulose-5-phosphate Ribulose-5-phosphate; Ribose-1-phosphate; Xylulose-5-phosphate Ricinoleic Acid Ricinoleic Acid 18:1 Hydroxy Ricinoleic acid-2 Ricinoleic acid-3 S-Acetyldihydrolipoamide (XC0086) S-Adenosylhomocysteine S-Adenosylmethionine S-Carboxymethylcysteine S-Methylcysteine S-Methylglutathione S-Methylmethionine S-Sulfocysteine Sarcosine SDMA Sedoheptulose-7-phosphate Ser Ser Ala / Thr gly Ser Glu Pro Thr Asp Pro Serotonin Sitosterol Spermidine Spermine Sphinganine Sphingomyelin (d18:1 / 16:0)-1 Sphingomyelin (d18:1 / 16:0)-2 Sphingomyelin (d18:1 / 18:0)-1 Sphingomyelin (d18:1 / 18:0)-2 Sphingosine Stearic acid Stearidonic Acid Stearoylethanolamide Stigmasterol-1 Stigmasterol-2 Succinic acid Sulfaguanidine (C-SCOPE IS) Sulfolitocholylglycine Taurine Taurochenodeoxycholic acid Taurocholic acid Taurodeoxycholic acid Taurolithocholic Acid Tauroursodeoxycholic acid Terephthalic Acid Theobromine; Aminophylline; Paraxanthine Thiamine Thiamine phosphate Thr Thr Ala Ala Thr Asp or Ser Glu Threo-3-hydroxyaspartic acid Threo-3-hydroxyaspartic acid-1 Threo-3-hydroxyaspartic acid-2 Threonate Thymidine Thyroxine Trans-Glutaconic Acid Trans-glutaconic acid; Itaconic acid Trichosyl acid Trigonelline Trilaurin Trimesic acid; Trimesic acid Trimethylamine Trimethylamine N-oxide Trimethylaminoacetone Trp Tyr UDP-galactose UDP-glucose Uracil urea uric acid Uridine Uridine; Pseudouridine Urocanic acid Ursodeoxycholic acid Val XA0005 XA0008 XA0009 XA0011 XA0017 XA0019 XA0023 XA0026 XA0033 XA0034 XA0037 XA0039 XA0052 Xanthosine XC0016 XC0039 XC0040 XC0047 XC0049 XC0054;XC0055;fA-Glu-Gly XC0056 XC0060 XC0063 XC0064 XC0065 XC0067 XC0070 XC0075 XC0088 XC0094 XC0101 XC0103 XC0107;fA-Glu-Gln XC0114;fA-Glu-His XC0117 XC0118 XC0119 XC0120 XC0126 XC0133 XC0135 XC0138 XC0139 XC0140 Zeaxanthin Alpha-tocopherol Alpha-tocopherol acetate β-Ala β-estradiol 17α-estradiol β-Hydroxyisovaleric Acid γ-Butyrobetaine γ-Glu-Ala γ-Glu-Arg γ-Glu-Asn γ-Glu-Asp γ-Glu-Citrulline γ-Glu-Gln γ-Glu-Glu γ-Glu-Gly γ-Glu-His γ-Glu-Leu γ-Glu-Lys γ-Glu-Met γ-Glu-ornithine γ-Glu-Phe γ-Glu-Ser γ-Glu-Taurine γ-Glu-Thr γ-Glu-Trp γ-Glu-Tyr γ-Glu-Val γ-Glu-Val-Gly Gamma-tocopherol [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 6] [Table 7-1] [Table 7-2] [Table 7-3] [Table 7-4] [Table 8-1] [Table 8-2]
Table 9-1
Table 9-2
Table 9-3
Table 9-4
Table 9-5
Table 9-6
Claims
1. 1. A method of treating, reducing the risk of, ameliorating, or preventing a vagus nerve-related disease, disorder, or condition, comprising: The method comprises administering to a subject in need thereof a composition comprising one or more microbial strains, or components thereof, or metabolic products thereof.
2. 1. A method of treating, reducing the risk of, ameliorating, or preventing a vagus nerve-related disease, disorder, or condition, comprising: The method comprises administering to a subject in need thereof a composition comprising one or more metabolites.
3. The vagus nerve-related disease, disorder, or condition is selected from the group consisting of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), autism spectrum disorder, rheumatoid arthritis, hypertension, heart failure, diabetes, arrhythmia, inflammatory bowel disease (IBD), fatty liver disease, depression, epilepsy, bipolar disorder, anxiety, post-traumatic stress disorder (PTSD), multiple sclerosis (MS), autoimmune disease, obesity, acute pancreatitis (AP), retinal ischemia / relapse, and chronic kidney disease.
3. The method of claim 1 or 2, wherein the condition is eye disease including I / R injury, chronic obstructive pulmonary disease (COPD), mood disorders, migraine and cluster headache, eating disorders, anorexia, psoriasis and psoriatic arthropathy, endocrine tumors and vagus paraganglioma, heartburn, gastroesophageal reflux disease (GERD), small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), celiac disease, chronic constipation, kidney disease, endometriosis, aging, or infertility including vascular disease.
4. 10. The method of any one of the preceding claims, wherein the method comprises treating, reducing the risk of, ameliorating, or preventing one or more of the following, or a combination: nerve cell damage, nerve ending damage, nerve fiber damage, brain damage, vagus nerve-associated organ damage.
5. 2. The method of any one of the preceding claims, wherein the subject is a mammal.
6. 2. The method of any one of the preceding claims, wherein the subject is a human.
7. 7. The method of any one of claims 1 or 3 to 6, wherein the one or more microbial strains are derived from a mammalian microbiota.
8. The method of any one of claims 1 or 3 to 7, wherein the one or more microbial strains are derived from the human microbiome.
9. The method of claim 8, wherein the human microbiota is the microbiota of the subject.
10. 10. The method of claim 9, wherein the human microbiota is administered to maintain or modulate the microbiota of the subject.
11. 10. The method of any one of the preceding claims, wherein the one or more components or metabolites are selected from Appendix 1, Appendix 3, or Appendix 4.
12. 10. The method of any one of the preceding claims, wherein the one or more metabolic products is or comprises a bile acid.
13. 10. The method of any one of the preceding claims, wherein the one or more metabolites is or comprises tauroursodeoxycholic acid.
14. 13. The method of any one of the preceding claims, wherein the one or more components or metabolites are butyrylcamitine, theobromine, p-hydroxyphenylpyruvic acid, propionic acid, picolinic acid, 2-hydroxy-4 methylvaleric acid, N6-acetylcysine, urocanic acid, N5-ethylglutamine, trigonelline, stachydrine, ectoine, 5-hydroxylysine, arginine (arg), cholic acid, 2-(4-hydroxyphenyl)propionic acid, N-acetyltryptophan, hydroxyproline, argininosuccinic acid, glutamic acid (Glu), sarcosine, 5-methoxyindoleacetic acid, indole-3-lactic acid, isovalerylalanine, N-acetylleucine, 1-methylhistidine, N-acetylphenylalanine, proline (Pro), or any combination thereof.
15. The one or more components or metabolites are 4-hydroxyphenylpyruvate, ectoine, gramine, N-acetyl-L-phenylalanine, nepsilon-acetyl-L-lysine, stachydrine, trigonelline, 3-ureidopropionic acid, theobromine, hippuric acid, imidazolepropionic acid, NG-methyl-L-arginine, trans-urocanic acid, N-acetyl-L-leucine, sarcosine, isobutyrylcarnitine, b-hydroxyisovalerate, Acid, L-theanine / N5-ethylglutamine, 5-hydroxylysine, phenaceturic acid, betaine, hydroxyproline, picolinic acid, 2-aminoadipic acid, glycerophosphocholine, carnitine, glycerol 3-phosphate, argininosuccinic acid, creatine, terephthalic acid, homocitrulline, mucic acid, homocysteine sulfinic acid, trimethyllysine, spermidine, glyoxylic acid, XA0013C6H6O4S, 3-indoxyl sulfate, 2. The method of any one of the preceding claims, wherein the anionic surfactant is selected from the group consisting of nicotinamide, N-formylglycine, ureidoglycolate, N-methylproline, glucaric acid, butyrylcarnitine, methionine sulfoxide, carboxymethyllysine, glycolic acid, phenaceturic acid, diethanolamine, phosphorylcholine, guanidinosuccinic acid, N-acetylhistidine, glyceric acid, S-methylmethionine, cysteine glutathione disulfide, kynurenine, N-acetylphenylalanine, threonic acid, malic acid, 7,8-dihydrobiopterin, homovanillic acid, taurocholic acid, 5-methoxyindoleacetic acid, butyrate, b-hydroxyisovaleric acid, 2-oxoglutaric acid, N-acetyltryptophan, thiaproline, hypotaurine, cholic acid, acetoacetic acid, ethanolamine, guanidoacetic acid, S-sulfocysteine, myristic acid C14: OXA0027, or any combination thereof.
16. 16. The method of any one of claims 1 or 3-15, wherein the one or more microbial strains are or comprise Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or combinations thereof.
17. 17. The method of any one of claims 1 or 3-16, wherein the one or more microbial strains are or comprise Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella sp., Bifidobacterium sp., or a combination thereof.
18. 18. The method of any one of claims 1 or 3-17, wherein the one or more microbial strains are or comprise Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus catus, Lactobacillus plantarum, Veillonella atypica, Bifidobacterium breve, or a combination thereof.
19. 20. The method of any one of claims 1 or 3-18, wherein the one or more microbial strains are or comprise Bacillus subtilis.
20. 20. The method of any one of claims 1 or 3-19, wherein the composition comprises two or more microbial strains.
21. 21. The method of any one of claims 1 or 3-20, wherein the composition comprises five or more microbial strains.
22. 22. The method of any one of claims 1 or 3-21, wherein the composition comprises 10 or more microbial strains.
23. 13. The method of any one of the preceding claims, wherein the composition is administered topically, orally, subcutaneously, intravenously, intramuscularly, intracerebrally, intrathecally, intrarectally, ophthalmically, intravitreally, or suprachoroidally.
24. 21. The method of claim 20, wherein the composition is administered orally.
25. 21. The method of claim 20, wherein the composition is administered intracerebrally.
26. 2. The method of any one of the preceding claims, wherein the composition is formulated as a syrup, liquid, tablet, troche, gummy, capsule, powder, gel, film, injectable, or eye drops.
27. Each microbial strain of the one or more microbial strains is 1 ~10 15 27. The method of any one of claims 1 or 3 to 26, wherein the microbial organism is present in the composition at a concentration of CFU.
28. Each of the one or more microbial strains is 6 28. The method of any one of claims 1 or 3 to 27, wherein the microbial organism is present in the composition at a concentration of CFU.
29. A composition for use in treating a vagus nerve-related disease, disorder, or condition, comprising one or more microbial strains, components thereof, or metabolic products thereof.
30. A composition for use in treating a vagus nerve-related disease, disorder, or condition, comprising one or more metabolites.
31. 30. The composition of claim 29, wherein the one or more microbial strains are derived from a mammalian microbiota.
32. 32. The composition of claim 29 or 31, wherein the one or more microbial strains are derived from the human microbiota.
33. The composition of claim 32, wherein the human microbiota is a subject's microbiota.
34. 34. The composition of claim 33, wherein the human microbiota is administered to maintain or modulate the microbiota of the subject.
35. 35. The composition of any one of claims 29 to 34, wherein the one or more components or metabolites are selected from Appendix 1, Appendix 3, or Appendix 4.
36. 36. The composition of any one of claims 29 to 35, wherein the one or more metabolites is or comprises a bile acid.
37. 37. The composition of any one of claims 29 to 36, wherein the one or more metabolites is or comprises tauroursodeoxycholic acid.
38. 36. The composition of any one of claims 29 to 35, wherein the one or more components or metabolites are butyrylcamitine, theobromine, p-hydroxyphenylpyruvic acid, propionic acid, picolinic acid, 2-hydroxy-4-methylvaleric acid, N6-acetylcysine, urocanic acid, N5-ethylglutamine, trigonelline, stachydrine, ectoine, 5-hydroxylysine, arginine (arg), cholic acid, 2-(4-hydroxyphenyl)propionic acid, N-acetyltryptophan, hydroxyproline, argininosuccinic acid, glutamic acid (Glu), sarcosine, 5-methoxyindoleacetic acid, indole-3-lactic acid, isovalerylalanine, N-acetylleucine, 1-methylhistidine, N-acetylphenylalanine, proline (Pro), or any combination thereof.
39. The one or more components or metabolites are 4-hydroxyphenylpyruvate, ectoine, gramine, N-acetyl-L-phenylalanine, nepsilon-acetyl-L-lysine, stachydrine, trigonelline, 3-ureidopropionic acid, theobromine, hippuric acid, imidazolepropionic acid, NG-methyl-L-arginine, transurocanic acid, N-acetyl-L-leucine, sarcosine, isobutyrylcarnitine, b-hydroxyisovaleric acid, , L-theanine / N5-ethylglutamine, 5-hydroxylysine, phenaceturic acid, betaine, hydroxyproline, picolinic acid, 2-aminoadipic acid, glycerophosphocholine, carnitine, glycerol 3-phosphate, argininosuccinic acid, creatine, terephthalic acid, homocitrulline, mucic acid, homocysteine sulfinic acid, trimethyllysine, spermidine, glyoxylic acid, XA0013C6H6O4S, 3-indoxyl sulfate, nicotinic acid 36. The composition of any one of claims 29 to 35, wherein the active ingredient is selected from the group consisting of tinamide, N-formylglycine, ureidoglycolate, N-methylproline, glucaric acid, butyrylcarnitine, methionine sulfoxide, carboxymethyllysine, glycolic acid, phenaceturic acid, diethanolamine, phosphorylcholine, guanidinosuccinic acid, N-acetylhistidine, glyceric acid, S-methylmethionine, cysteine glutathione disulfide, kynurenine, N-acetylphenylalanine, threonic acid, malic acid, 7,8-dihydrobiopterin, homovanillic acid, taurocholic acid, 5-methoxyindoleacetic acid, butyrate, b-hydroxyisovaleric acid, 2-oxoglutaric acid, N-acetyltryptophan, thiaproline, hypotaurine, cholic acid, acetoacetic acid, ethanolamine, guanidoacetic acid, S-sulfocysteine, myristic acid C14: OXA0027, or any combination thereof.
40. 40. The composition of any one of claims 29 or 31-39, wherein the one or more microbial strains are or comprise Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or combinations thereof.
41. 41. The composition of any one of claims 29 or 31-40, wherein the one or more microbial strains are or comprise Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella sp., Bifidobacterium sp., or a combination thereof.
42. 42. The composition of any one of claims 29 or 31-41, wherein the one or more microbial strains are or comprise Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus catus, Lactobacillus plantarum, Veillonella atypica, Bifidobacterium breve, or a combination thereof.
43. 43. The composition of any one of claims 29 or 31-42, wherein the one or more microbial strains are or comprise Bacillus subtilis.
44. 44. The composition of any one of claims 29 or 31-43, wherein the composition comprises two or more microbial strains.
45. 45. The composition of any one of claims 29 or 31-44, wherein the composition comprises five or more microbial strains.
46. 46. The composition of any one of claims 29 or 31-45, wherein the composition comprises 10 or more microbial strains.
47. 47. The composition of any one of claims 29 to 46, wherein the composition is for topical, oral, subcutaneous, intravenous, intramuscular, intracerebral, intrathecal, rectal, intraocular, intravitreal, or suprachoroidal administration.
48. 48. The composition of claim 47, wherein the composition is for oral administration.
49. The composition of claim 47, wherein the composition is for intracerebral administration.
50. The composition of any one of claims 29 to 49, wherein the composition is formulated as a syrup, liquid, tablet, troche, gummy, capsule, powder, gel, film, injectable, or eye drops.
51. Each microbial strain of the one or more microbial strains is 1 ~10 15 51. The composition of any one of claims 29 or 31-50, wherein the composition is present in a concentration of CFU.
52. Each of the one or more microbial strains is 6 51. The composition of any one of claims 29 or 31-50, wherein the composition is present in a concentration of CFU.
53. 53. Use of a composition according to any one of claims 29 to 52 for modulating one or more metabolites in a subject.
54. 53. Use of a composition according to any one of claims 29 to 52 for modulating one or more characteristics in a subject.
55. The one or more features are (i) the level of cell survival; (ii) the level or activity of a nucleic acid or protein, or a form thereof; (iii) mitochondrial function; (iv) peroxisomal function; (v) ATP levels; (vi) proteasome function; (vii) lysosomal function; (viii) oxidative stress, (ix) inflammation; (x) nerve damage (e.g., due to beta amyloid, tangles, etc.); (xi) nerve fiber damage, (xii) Damage to nerve endings, or (xiii) use of the composition of claim 54, which is or comprises brain injury.
56. 53. Use of a composition according to any one of claims 29 to 52 for characterising the ability of one or more microbial strains to modulate one or more metabolites in a subject.
57. 53. Use of the composition of any one of claims 29 to 52 for treating or ameliorating a disease, disorder, or condition in a subject, wherein the disease, disorder, or condition is associated with one or more metabolic products.
58. 58. The use of the composition of claim 57, wherein the disease, disorder or condition is AD, PD, ALS, autism spectrum disorder, rheumatoid arthritis, hypertension, heart failure, diabetes, arrhythmia, IBD, fatty liver disease, depression, epilepsy, bipolar disorder, anxiety, PTSD, MS, autoimmune diseases, obesity, AP, eye diseases including retinal ischemia / reperfusion (I / R) injury, COPD, mood disorders, migraine and cluster headaches, eating disorders, anorexia, psoriasis and psoriatic arthropathy, endocrine tumors and vagus paragangliomas, heartburn, GERD, SIBO, IBS, celiac disease, chronic constipation, kidney disease, endometriosis, aging, or infertility including vascular disease.
59. 59. Use of the composition of claim 58, wherein the use comprises treating, reducing the risk of, ameliorating, or preventing one or more of the following, or a combination: nerve cell damage, nerve ending damage, nerve fiber damage, brain damage, vagus nerve-associated organ damage.
60. 1. A method for screening a microbial strain, comprising: contacting the microbial strain with a culture comprising a neuronal cell or neuronal cell line that models a vagus nerve-related disease, disorder, or condition; and determining whether the microbial strain has altered a characteristic of the culture, the characteristic being associated with the vagus nerve-associated disease, disorder, or condition.
61. 61. The method of claim 60, wherein said determining step comprises comparing said characteristics before and after performance of said contacting step.
62. 61. The method of claim 60, wherein the determining step comprises comparing the characteristic to an equivalent reference after the contacting step.
63. 63. The method of claim 62, wherein the equivalent reference is a historical reference.
64. 64. The method of claim 63, wherein the comparable reference is a negative control reference.
65. 64. The method of claim 63, wherein the comparable reference is a positive control reference.
66. The method of any one of claims 60 to 65, wherein the characteristic is the level of cell survival.
67. 66. The method of any one of claims 60 to 65, wherein the characteristic is the level or activity of a nucleic acid or protein, or a form thereof.
68. 66. The method of any one of claims 60 to 65, wherein the characteristic is or comprises one or more of a mitochondrial function, a peroxisomal function, a proteasomal function, or a lysosomal function.
69. 66. The method of any one of claims 60 to 65, wherein the characteristic is or comprises inflammation.
70. 66. The method of any one of claims 60 to 65, wherein the characteristic is or comprises ATP levels.
71. 66. The method of any one of claims 60 to 65, wherein the characteristic is or comprises one or more of cell damage (e.g. neuronal cells).
72. 66. The method of any one of claims 60-65, wherein the characteristic is or includes one or more of nerve damage (e.g., due to beta amyloid, tangles, etc.), nerve fiber damage, nerve ending damage, or brain damage.
73. 66. The method of any one of claims 60 to 65, wherein the characteristic is or comprises oxidative stress.
74. The microbial strain alters one or more characteristics of the culture, the one or more characteristics being associated with the vagus nerve-related disease, disorder, or condition, the one or more characteristics being: (i) the level of cell survival; (ii) the level or activity of a nucleic acid or protein, or a form thereof; (iii) mitochondrial function; (iv) peroxisomal function; (v) ATP levels; (vi) proteasome function; (vii) lysosomal function; (viii) oxidative stress, (ix) inflammation; (x) nerve damage (e.g., due to beta amyloid, tangles, etc.); (xi) nerve fiber damage, (xii) Damage to nerve endings, or (xiii) A method according to any one of claims 60 to 65, which is or comprises brain injury.
75. 1. A method comprising: The method comprises administering to a subject in need thereof a composition comprising one or more microbial strains, or components thereof, or metabolic products thereof.
76. 1. A method comprising: The method comprises administering to a subject in need thereof a composition comprising one or more metabolites.
77. 77. The method of claim 75 or 76, wherein the subject is a mammal.
78. The method of any one of claims 75 to 77, wherein the subject is a human.
79. 79. The method of any one of claims 75 or 77-78, wherein the one or more microbial strains are derived from a mammalian microbiota.
80. 80. The method of any one of claims 75 or 77 to 79, wherein the one or more microbial strains are derived from the human microbiome.
81. 81. The method of claim 80, wherein the human microbiota is the microbiota of the subject.
82. 82. The method of claim 81, wherein the human microbiota is administered to maintain or modulate the microbiota of the subject.
83. 83. The method of any one of claims 75 to 82, wherein the one or more components or metabolites are selected from Appendix 1, Appendix 3, or Appendix 4.
84. 84. The method of any one of claims 75 to 83, wherein the one or more metabolites is or comprises a bile acid.
85. 85. The method of any one of claims 75 to 84, wherein the one or more metabolites is or comprises tauroursodeoxycholic acid.
86. 84. The method of any one of claims 75 to 83, wherein the one or more components or metabolites are butyrylcamitine, theobromine, p-hydroxyphenylpyruvic acid, propionic acid, picolinic acid, 2-hydroxy-4-methylvaleric acid, N6-acetylcysine, urocanic acid, N5-ethylglutamine, trigonelline, stachydrine, ectoine, 5-hydroxylysine, arginine (arg), cholic acid, 2-(4-hydroxyphenyl)propionic acid, N-acetyltryptophan, hydroxyproline, argininosuccinic acid, glutamic acid (Glu), sarcosine, 5-methoxyindoleacetic acid, indole-3-lactic acid, isovalerylalanine, N-acetylleucine, 1-methylhistidine, N-acetylphenylalanine, proline (Pro), or any combination thereof.
87. The one or more components or metabolites are 4-hydroxyphenylpyruvate, ectoine, gramine, N-acetyl-L-phenylalanine, nepsilon-acetyl-L-lysine, stachydrine, trigonelline, 3-ureidopropionic acid, theobromine, hippuric acid, imidazolepropionic acid, NG-methyl-L-arginine, trans-urocanic acid, N-acetyl-L-leucine, sarcosine, isobutyrylcarnitine, b-hydroxyisovalerate, Acid, L-theanine / N5-ethylglutamine, 5-hydroxylysine, phenaceturic acid, betaine, hydroxyproline, picolinic acid, 2-aminoadipic acid, glycerophosphocholine, carnitine, glycerol 3-phosphate, argininosuccinic acid, creatine, terephthalic acid, homocitrulline, mucic acid, homocysteine sulfinic acid, trimethyllysine, spermidine, glyoxylic acid, XA0013C6H6O4S, 3-indoxyl sulfate, Ni 84. The method of any one of claims 75 to 83, wherein the glyceryl ester is selected from the group consisting of cotinamide, N-formylglycine, ureidoglycolate, N-methylproline, glucaric acid, butyrylcarnitine, methionine sulfoxide, carboxymethyllysine, glycolic acid, phenaceturic acid, diethanolamine, phosphorylcholine, guanidinosuccinic acid, N-acetylhistidine, glyceric acid, S-methylmethionine, cysteine glutathione disulfide, kynurenine, N-acetylphenylalanine, threonic acid, malic acid, 7,8-dihydrobiopterin, homovanillic acid, taurocholic acid, 5-methoxyindoleacetic acid, butyrate, b-hydroxyisovaleric acid, 2-oxoglutaric acid, N-acetyltryptophan, thiaproline, hypotaurine, cholic acid, acetoacetic acid, ethanolamine, guanidoacetic acid, S-sulfocysteine, myristic acid C14: OXA0027, or any combination thereof.
88. 88. The method of any one of claims 75 or 77-87, wherein the one or more microbial strains are or comprise Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or combinations thereof.
89. 89. The method of any one of claims 75 or 77-88, wherein the one or more microbial strains are or comprise Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella sp., Bifidobacterium sp., or a combination thereof.
90. 90. The method of any one of claims 75 or 77-89, wherein the one or more microbial strains are or comprise Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus catus, Lactobacillus plantarum, Veillonella atypica, Bifidobacterium breve, or a combination thereof.
91. 91. The method of any one of claims 75 or 77-90, wherein the one or more microbial strains are or comprise Bacillus subtilis.
92. 92. The method of any one of claims 75 or 77-91, wherein the composition comprises two or more microbial strains.
93. 93. The method of any one of claims 75 or 77-92, wherein the composition comprises five or more microbial strains.
94. 94. The method of any one of claims 75 or 77-93, wherein the composition comprises 10 or more microbial strains.
95. 95. The method of any one of claims 75-94, wherein the composition is administered topically, orally, subcutaneously, intravenously, intramuscularly, intracerebrally, intrathecally, intrarectally, ophthalmically, intravitreally, or suprachoroidally.
96. 96. The method of claim 95, wherein the composition is administered orally.
97. 96. The method of claim 95, wherein the composition is administered intracerebrally.
98. 98. The method of any one of claims 75-97, wherein the composition is formulated as a syrup, liquid, tablet, troche, gummy, capsule, powder, gel, film, injectable, or eye drops.
99. Each microbial strain of the one or more microbial strains is 1 ~10 15 99. The method of any one of claims 75 or 77-98, wherein the composition is present at a concentration of CFU.
100. Each of the one or more microbial strains is 6 100. The method of any one of claims 75 or 77-99, wherein the compound is present in the composition at a concentration of CFU.
101. 101. The method of any one of claims 75 to 100, wherein said microbial strain or said metabolite has an altered characteristic of said subject.
102. 102. The method of claim 101, wherein the characteristic is a level of cell viability.
103. 102. The method of claim 101, wherein the characteristic is the level or activity of a nucleic acid or protein, or a form thereof.
104. 102. The method of claim 101, wherein the characteristic is or comprises one or more of a mitochondrial function, a peroxisomal function, a proteasomal function, or a lysosomal function.
105. 102. The method of claim 101, wherein the characteristic is or comprises inflammation.
106. 102. The method of claim 101, wherein the characteristic is or comprises ATP levels.
107. 102. The method of claim 101, wherein the characteristic is or includes one or more of cell damage (e.g., neuronal cell).
108. 102. The method of claim 101, wherein the characteristic is or includes one or more of nerve damage (e.g., due to beta amyloid, tangles, etc.), nerve fiber damage, nerve ending damage, or brain damage.
109. 102. The method of claim 101, wherein the characteristic is or comprises oxidative stress.
110. The microbial strain alters one or more characteristics of the subject, the one or more characteristics being: (i) the level of cell survival; (ii) the level or activity of a nucleic acid or protein, or a form thereof; (iii) mitochondrial function; (iv) peroxisomal function; (v) ATP levels; (vi) proteasome function; (vii) lysosomal function; (viii) oxidative stress, (ix) inflammation; (x) nerve damage (e.g., due to beta amyloid, tangles, etc.); (xi) nerve fiber damage, (xii) Damage to nerve endings, or (xiii) the method of claim 101, which is or comprises brain injury.
111. 111. The method of any one of claims 101 to 110, wherein the characteristic is associated with the vagus nerve-related disease, disorder, or condition.
112. 1. A method for characterizing a microbial strain, comprising: adding said microbial strain to a culture comprising a neuronal cell or neuronal cell line that models a vagus nerve-related disease, disorder, or condition; and determining whether the microbial strain affects the level of one or more characteristics of the neuronal cell or neuronal cell line, wherein the one or more characteristics are associated with the vagus nerve-related disease, disorder, or condition.
113. 1. A method of manufacturing a pharmaceutical treatment comprising characterizing one or more microbial strains, components, or metabolic products thereof, comprising: adding said one or more microbial strains to a culture comprising a neuronal cell or neuronal cell line that models a vagus nerve-related disease, disorder, or condition; determining whether the one or more microbial strains affect the level of one or more characteristics of the neuronal cell or neuronal cell line, wherein the one or more characteristics are associated with the vagus nerve-related disease, disorder, or condition.
114. 1. A method of manufacturing a pharmaceutical treatment comprising: The method comprises adding one or more microbial strains, components, or metabolites thereof to a syrup, liquid, tablet, lozenge, gummy, capsule, powder, gel, film, injectable, or eye drop.
115. 1. A method of manufacturing a pharmaceutical treatment comprising: The method comprises adding one or more metabolites to a syrup, liquid, tablet, lozenge, gummy, capsule, powder, gel, film, injectable, or eye drop.
116. 1. A method for evaluating a microbial strain for its ability to affect one or more characteristics of a culture, comprising: adding said microbial strain to said culture comprising a neuronal cell or neuronal cell line that models a vagus nerve-related disease, disorder, or condition; and determining whether the microbial strain affects the level of one or more characteristics of the neuronal cell or neuronal cell line, wherein the one or more characteristics are associated with the vagus nerve-related disease, disorder, or condition.
117. determining a level of one or more characteristics of said neuronal cells or neuronal cell line in said culture prior to adding said microbial strain to said culture; determining the level of the same one or more characteristics of the neuronal cells or neuronal cell line in the culture after adding the microbial strain to the culture; 117. The method of any one of claims 112 to 116, further comprising comparing the level of the one or more characteristics determined before adding the microbial strain with the level of the one or more characteristics determined after adding the microbial strain.
118. The one or more features are (i) the level of cell survival; (ii) the level or activity of a nucleic acid or protein, or a form thereof; (iii) mitochondrial function; (iv) peroxisomal function; (v) ATP levels; (vi) proteasome function; (vii) lysosomal function; (viii) oxidative stress, (ix) inflammation; (x) nerve damage (e.g., due to beta amyloid, tangles, etc.); (xi) nerve fiber damage, (xii) nerve ending damage, (xiii) Brain injury; or (xiv) The method of any one of claims 112 to 117, including combinations thereof.
119. 119. The method of any one of claims 60 to 118, wherein the disease, disorder, or condition is AD, PD, ALS, autism spectrum disorder, rheumatoid arthritis, hypertension, heart failure, diabetes, arrhythmia, IBD, fatty liver disease, depression, epilepsy, bipolar disorder, anxiety, PTSD, MS, autoimmune disease, obesity, AP, eye disease including retinal ischemia / reperfusion (I / R) injury, COPD, mood disorders, migraine and cluster headaches, eating disorders, anorexia nervosa, psoriasis and psoriatic arthropathy, endocrine tumors and vagus paragangliomas, heartburn, GERD, SIBO, IBS, celiac disease, chronic constipation, kidney disease, endometriosis, aging, or infertility including vascular disease.
120. A composition for use in the treatment or prevention of a vagus nerve-related disease, disorder, or condition, comprising one or more microbial strains, components thereof, or metabolic products thereof.
121. A composition for use in the treatment or prevention of a vagus nerve-related disease, disorder, or condition, comprising one or more metabolites.
122. The use of claim 120, wherein the one or more microbial strains are derived from a mammalian microbiota.
123. 123. The use according to claim 120 or 122, wherein the one or more microbial strains are derived from the human microbiome.
124. The use described in claim 123, wherein the human microbiota is the microbiota of the subject.
125. The use of claim 124, wherein the human microbiota is administered to maintain or modulate the microbiota of the subject.
126. 126. The use of any one of claims 120 to 125, wherein the one or more components or metabolites are selected from Appendix 1, Appendix 3, or Appendix 4.
127. 127. The use according to any one of claims 120 to 126, wherein the one or more metabolites is or comprises a bile acid.
128. 128. The use of any one of claims 120 to 127, wherein the one or more metabolites is or comprises tauroursodeoxycholic acid.
129. 127. The use of any one of claims 120 to 126, wherein the one or more components or metabolites are butyrylcamitine, theobromine, p-hydroxyphenylpyruvic acid, propionic acid, picolinic acid, 2-hydroxy-4-methylvaleric acid, N6-acetylcysine, urocanic acid, N5-ethylglutamine, trigonelline, stachydrine, ectoine, 5-hydroxylysine, arginine (arg), cholic acid, 2-(4-hydroxyphenyl)propionic acid, N-acetyltryptophan, hydroxyproline, argininosuccinic acid, glutamic acid (Glu), sarcosine, 5-methoxyindoleacetic acid, indole-3-lactic acid, isovalerylalanine, N-acetylleucine, 1-methylhistidine, N-acetylphenylalanine, proline (Pro), or any combination thereof.
130. The one or more components or metabolites are 4-hydroxyphenylpyruvate, ectoine, gramine, N-acetyl-L-phenylalanine, nepsilon-acetyl-L-lysine, stachydrine, trigonelline, 3-ureidopropionic acid, theobromine, hippuric acid, imidazolepropionic acid, NG-methyl-L-arginine, transurocanic acid, N-acetyl-L-leucine, sarcosine, isobutyrylcarnitine, b-hydroxyisovaleric acid, , L-theanine / N5-ethylglutamine, 5-hydroxylysine, phenaceturic acid, betaine, hydroxyproline, picolinic acid, 2-aminoadipic acid, glycerophosphocholine, carnitine, glycerol 3-phosphate, argininosuccinic acid, creatine, terephthalic acid, homocitrulline, mucic acid, homocysteine sulfinic acid, trimethyllysine, spermidine, glyoxylic acid, XA0013C6H6O4S, 3-indoxyl sulfate, nicotinic acid Tinamide, N-formylglycine, ureidoglycolate, N-methylproline, glucaric acid, butyrylcarnitine, methionine sulfoxide, carboxymethyllysine, glycolic acid, phenaceturic acid, diethanolamine, phosphorylcholine, guanidinosuccinic acid, N-acetylhistidine, glyceric acid, S-methylmethionine, cysteine glutathione disulfide, kynurenine, N-acetylphenylalanine, threonic acid, apple 127. The use of any one of claims 120 to 126, wherein the acetylcholinesterase is selected from the group consisting of acetylcholine, ...
131. 131. The use of any one of claims 120 or 122-130, wherein the one or more microbial strains are or comprise Gluconacetobacter hansenii, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or a combination thereof.
132. 132. The use according to any one of claims 120 or 122 to 131, wherein the one or more microbial strains are or comprise Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus sp., Lactobacillus plantarum, Veillonella sp., Bifidobacterium sp., or a combination thereof.
133. 133. The use of any one of claims 120 or 122-132, wherein the one or more microbial strains are or comprise Gluconacetobacter hanseni, Terrisporobacter glycolicus, Coprococcus catus, Lactobacillus plantarum, Veillonella atypica, Bifidobacterium breve, or a combination thereof.
134. 134. The use according to any one of claims 120 or 122 to 133, wherein the one or more microbial strains are or comprise Bacillus subtilis.
135. 135. The use according to any one of claims 120 or 122 to 134, wherein the composition comprises two or more microbial strains.
136. 136. The use according to any one of claims 120 or 122 to 135, wherein the composition comprises five or more microbial strains.
137. 137. The use according to any one of claims 120 or 122 to 136, wherein the composition comprises 10 or more microbial strains.
138. 138. The use according to any one of claims 120 to 137, wherein the composition is for topical, oral, subcutaneous, intravenous, intramuscular, intracerebral, intrathecal, rectal, intraocular, intravitreal, or suprachoroidal administration.
139. 139. The use of claim 138, wherein the composition is for oral administration.
140. The use described in claim 138, wherein the composition is for intracerebral administration.
141. The use of any one of claims 120 to 140, wherein the composition is formulated as a syrup, liquid, tablet, troche, gummy, capsule, powder, gel, film, injectable, or eye drops.
142. Each microbial strain of the one or more microbial strains is 1 ~10 15 142. The use of any one of claims 120 or 122 to 141, wherein the composition is present at a concentration of CFU.
143. Each of the one or more microbial strains is 6 142. The use of any one of claims 120 or 122 to 141, wherein the composition is present at a concentration of CFU.
144. 144. The use of any one of claims 120 to 143, wherein the vagus nerve related disease, disorder or condition is AD, PD, ALS, autism spectrum disorder, rheumatoid arthritis, hypertension, heart failure, diabetes, arrhythmia, IBD, fatty liver disease, depression, epilepsy, bipolar disorder, anxiety, PTSD, MS, autoimmune diseases, obesity, AP, eye diseases including retinal ischemia / reperfusion (I / R) injury, COPD, mood disorders, migraine and cluster headaches, eating disorders, anorexia, psoriasis and psoriatic arthropathy, endocrine tumors and vagus nerve paragangliomas, heartburn, GERD, SIBO, IBS, celiac disease, chronic constipation, kidney disease, endometriosis, aging, or infertility including vascular disease.
145. The use of claim 144, wherein the use comprises treating, reducing the risk of, ameliorating, or preventing one or more of the following, or a combination: nerve cell damage, nerve ending damage, nerve fiber damage, brain damage, vagus nerve-associated organ damage.
146. An injection comprising the composition according to any one of claims 29 to 52.
147. A dietary supplement comprising a composition according to any one of claims 29 to 52.
148. 121. A kit comprising a composition according to any one of claims 29 to 52 or 120 for use in the treatment or prevention of a vagus nerve-related disease, disorder or condition.
